Defects in Metabolism of Lipids

Published on 25/03/2015 by admin

Filed under Pediatrics

Last modified 22/04/2025

Print this page

rate 1 star rate 2 star rate 3 star rate 4 star rate 5 star
Your rating: none, Average: 0 (0 votes)

This article have been viewed 4017 times

Chapter 80 Defects in Metabolism of Lipids

80.1 Disorders of Mitochondrial Fatty Acid β-Oxidation

Mitochondrial β-oxidation of fatty acids is an essential energy-producing pathway. It is a particularly important pathway during prolonged periods of starvation, and during periods of reduced caloric intake due to gastrointestinal illness or increased energy expenditure during febrile illness. Under these conditions, the body switches from using predominantly carbohydrate to predominantly fat as its major fuel. Fatty acids are also important fuels for exercising skeletal muscle and are the preferred substrate for the heart. In these tissues, fatty acids are completely oxidized to carbon dioxide and water. The end products of hepatic fatty acid oxidation are the ketone bodies β-hydroxybutyrate and acetoacetate. These cannot be oxidized by the liver but serve as important fuels in peripheral tissues, particularly the brain.

Genetic defects have been identified in nearly all of the known steps in the fatty acid oxidation pathway; all are recessively inherited (Table 80-1).

Clinical manifestations characteristically involve the tissues with a high β-oxidation flux including liver, skeletal, and cardiac muscle. The most common presentation is an acute episode of life-threatening coma and hypoglycemia induced by a period of fasting due to defective hepatic ketogenesis. Other manifestations include chronic cardiomyopathy and muscle weakness or exercise-induced acute rhabdomyolysis. The fatty acid oxidation defects can be asymptomatic during periods when there is no fasting stress. Acutely presenting disease may be misdiagnosed as Reye syndrome or, if fatal, as sudden unexpected infant death. Fatty acid oxidation disorders are easily overlooked because the only specific clue to the diagnosis may be the finding of inappropriately low concentrations of urinary ketones in an infant who has hypoglycemia. Genetic defects in ketone body utilization may be overlooked because ketosis is an expected finding with fasting hypoglycemia. In some circumstances, clinical manifestations appear to arise from toxic effects of fatty acid metabolites rather than inadequate energy production. These include disorders (LCHAD, CPT-IA, TFP) in which the presence of a homozygous affected fetus increases the risk of a life-threatening illness in the heterozygote mother, resulting in acute fatty liver of pregnancy or preeclampsia with HELLP (hemolysis, elevated liver enzymes, low platelets) syndrome. Malformations of the brain and kidneys have been described in severe electron transfer flavoprotein (ETF), ETF dehydrogenase (ETF-DH), and carnitine palmitoyltransferase-2 (CPT-II) deficiencies that might reflect in utero toxicity of fatty acid metabolites. Progressive retinal degeneration, peripheral neuropathy and chronic progressive liver disease have been identified in LCHAD and TFP deficiency. Newborn screening programs using tandem mass spectrometry (MS/MS) detect characteristic acylcarnitines seen in many of these disorders and permit presymptomatic diagnosis. Screening programs have provided evidence that all the fatty acid oxidation disorders combined are among the most common inborn errors of metabolism.

Figures 80-1 and 80-2 outline the steps involved in the oxidation of a typical long-chain fatty acid. In the carnitine cycle, fatty acids are transported across the barrier of the inner mitochondrial membrane as acylcarnitine esters. Within the mitochondria, successive turns of the 4-step β-oxidation cycle convert the coenzyme A (CoA)-activated fatty acid to acetyl CoA units. Two to three different chain-length specific isoenzymes are needed for each of these β-oxidation steps to accommodate the different-sized fatty acyl CoA species. The electron transfer pathway carries electrons generated in the 1st β-oxidation step (acyl CoA dehydrogenase) to the electron transport chain for adenosine triphosphate (ATP) production, while electrons generated from the third step (3-hydroxyacyl CoA dehydrogenase) enter the respiratory chain at the level of complex 1. Most of the acetyl CoA generated from hepatic β-oxidation flows through the pathway of ketogenesis to form β-hydroxybutyrate and acetoacetate.

image

Figure 80-1 Mitochondrial fatty acid oxidation. Carnitine enters the cell through the action of the organic cation/carnitine transporter (OCTN2). Palmitate, a typical 16-carbon long-chain fatty acid, is transported across the plasma membrane and can be activated to form a long-chain (LC) fatty acyl coenzyme A (CoA). It then enters into the carnitine cycle, where it is transesterified by carnitine palmitoyltransferase-I (CPT-I), translocated across the inner mitochondrial membrane by carnitine/acylcarnitine translocase (TRANS), and then reconverted into a long-chain fatty acyl CoA by carnitine palmitoyltransferase-II (CPT-II) to undergo β-oxidation. Very long chain acyl CoA dehydrogenase (VLCAD/LCAD) leads to the production of (C16-10) 2,3 enoyl CoA. Trifunctional protein (TFP) contains the activities of enoyl CoA hydratase (hydratase), 3-OH-hydroxyacyl CoA dehydrogenase (3-OH-ACD), and β-ketothiolase (thiolase). Acetyl CoA, FADH, and NADH are produced. Medium- and short-chain fatty acids (C8-4) can enter the mitochondrial matrix independent of the carnitine cycle. Medium-chain acyl CoA dehydrogenase (MCAD), short-chain acyl CoA dehydrogenase (SCAD), and short-chain hydroxy acyl CoA dehydrogenase (SCHAD) are required. Acetyl CoA can then enter the Krebs (TCA) cycle. Electrons are transported from FADH to the respiratory chain via the electron transfer flavoprotein (ETF) and the electron transfer flavoprotein dehydrogenase (ETF-DH). NADH enters the electron transport chain through complex I. Acetyl CoA can be converted into hydroxymethylglutaryl (HMG) CoA by β-hydroxy-β-methylglutaryl CoA synthase (HMG CoA synthase) and then the ketone body acetoacetate by the action of β-hydroxy-β-methylglutaryl CoA lyase (HMG CoA lyase).

Defects in the β-Oxidation Cycle

Medium-Chain Acyl CoA Dehydrogenase (MCAD) Deficiency

MCAD deficiency is the most common fatty acid oxidation disorder. The disorder shows a strong founder effect; most patients have a northwestern European ancestry, and the majority of patients are homozygous for a single common missense mutation, an A-G transition at cDNA position 985 that changes a lysine to glutamic acid at residue 329 (K329E).

Laboratory Findings

During acute episodes, hypoglycemia is usually present. Plasma and urinary ketone concentrations are inappropriately low (hypoketotic hypoglycemia). Because of the relative hypoketonemia, there is little or no metabolic acidemia. Tests of liver function are abnormal, with elevations of liver enzymes (ALT, AST), elevated blood ammonia, and prolonged prothrombin (PT) and partial thromboplastin times (PTT). Liver biopsy at times of acute illness shows microvesicular or macrovesicular steatosis due to triglyceride accumulation. During fasting stress or at times of acute illness, urinary organic acid profiles by gas chromatography/mass spectrometry show inappropriately low concentrations of ketones and elevated levels of medium-chain dicarboxylic acids (adipic, suberic, and sebacic acids) that derive from microsomal and peroxisomal omega oxidation of fatty acids. Plasma and tissue concentrations of total carnitine are reduced to 25-50% of normal, and the fraction of total esterified carnitine is increased. This pattern of secondary carnitine deficiency is seen in most fatty acid oxidation defects and reflects competition between increased acylcarnitine levels and free carnitine transport at the plasma membrane. Significant exceptions to this rule are the plasma membrane carnitine transporter, CPT-IA and β-hydroxy-β-methylglutaryl CoA (HMG CoA) synthase deficiencies.

Diagnostic patterns include increased plasma C8:0, C10:0, and C10:1 acylcarnitine species and increased urinary acylglycines including hexanoyl-, suberyl- and 3-phenylpropionyl glycines. Newborn screening programs using tandem mass spectrometry which almost all babies born in the USA receive can diagnose presymptomatic MCAD deficiency based on the detection of the abnormal acylcarnitines in filter paper blood spots. In many cases, the diagnosis can be confirmed by finding the common A985G mutation. A second common variant, T199C, has been detected in infants with characteristic acylcarnitines in newborn screening tests. Interestingly, this allele has not been seen to date in symptomatic MCAD patients; it may represent a mild mutation.

Treatment

Acute illnesses should be promptly treated with intravenous fluids containing 10% dextrose to treat or prevent hypoglycemia and to suppress lipolysis as rapidly as possible (Chapter 86). Chronic therapy consists of avoiding fasting. This usually requires simply adjusting the diet to ensure that overnight fasting periods are limited to <10-12 hr. Restricting dietary fat or treatment with carnitine is controversial. The necessity for active therapeutic intervention for individuals with the T199C variant has not yet been established.

Very Long Chain Acyl CoA Dehydrogenase (VLCAD) Deficiency

VLCAD deficiency is the second most commonly diagnosed disorder of fatty acid oxidation. It was originally termed LCAD deficiency before the existence of the inner mitochondrial membrane-bound VLCAD was known. All patients previously diagnosed as having LCAD deficiency have VLCAD enzyme deficiency. Patients with VLCAD deficiency are usually more severely affected than those with MCAD deficiency, presenting earlier in infancy and having more chronic problems with muscle weakness or episodes of muscle pain and rhabdomyolysis. Cardiomyopathy may be present during acute attacks associated with fasting. The left ventricle may be hypertrophic or dilated and show poor contractility on echocardiography. Sudden unexpected death has occurred in several patients, but most who survived the initial episode showed improvement, including normalization of cardiac function. Other physical and routine laboratory features are similar to those of MCAD deficiency, including secondary carnitine deficiency. The urinary organic acid profile shows a nonketotic dicarboxylic aciduria. Increased levels of C6-12 dicarboxylic acids may be noted in the urine. Diagnosis may be suggested by an abnormal acylcarnitine profile with plasma or blood spot C14:1,14:0 acylcarnitine species, but the specific diagnosis requires assay of enzyme activities of VLCAD in cultured fibroblasts or direct mutational analysis of the VLCAD gene. Treatment is based primarily on avoidance of fasts for >10-12 hr. Continuous intragastric feeding is useful in some patients.

Long-Chain 3-Hydroxyacyl CoA Dehydrogenase (LCHAD)/Mitochondrial Trifunctional Protein (TFP) Deficiency

The LCHAD enzyme is part of a mitochondrial trifunctional protein (TFP), which also contains two other steps in β-oxidation, long-chain enoyl CoA hydratase and long-chain β-ketothiolase. It is a hetero-octameric protein composed of 4 α and 4 β chains that derive from distinct contiguous genes with a common promoter region. In some patients, only the LCHAD activity of the TFP is affected (LCHAD deficiency), whereas others have deficiencies of all 3 activities (TFP deficiency).

Clinical manifestations include attacks of acute hypoketotic hypoglycemia similar to MCAD deficiency; patients often show evidence of more severe disease, including cardiomyopathy, muscle cramps and weakness, and abnormal liver function (cholestasis). Toxic effects of fatty acid metabolites may produce pigmented retinopathy, progressive liver failure, peripheral neuropathy, and rhabdomyolysis. Life-threatening obstetric complications; acute fatty liver of pregnancy; and hemolysis, elevated liver enzymes, low platelets (HELLP) syndrome are observed in heterozygous mothers carrying homozygotic fetuses affected with LCHAD/TFP deficiency. Sudden unexpected infant death may occur. The diagnosis is indicated by elevated levels of blood spot or plasma 3-hydroxy acylcarnitines of chain lengths C16-C18. Urinary organic acid profile in patients may show increases in levels of 3-hydroxydicarboxylic acids of chain lengths C6-C14. Secondary carnitine deficiency is common. A common mutation in the α subunit, E474Q, is seen in >60% of LCHAD deficient patients. This mutation in the fetus is significantly associated with the obstetric complications, but other mutations in either subunit may also be associated with maternal illness.

Treatment is similar to that for MCAD or VLCAD deficiency; that is, avoiding fasting stress. Some investigators have suggested that dietary supplements with medium-chain triglyceride oil to by-pass the long-chain fatty acid oxidation process for long-chain defects and docosahexaenoic acid (DHA, for protection against the retinal changes) may be useful. Liver transplantation does not ameliorate the metabolic abnormalities.

Defects in the Carnitine Cycle

Plasma Membrane Carnitine Transport Defect (Primary Carnitine Deficiency)

Primary carnitine deficiency is the only genetic defect in which carnitine deficiency is the cause, rather than the consequence, of impaired fatty acid oxidation. The most common presentation is progressive cardiomyopathy with or without skeletal muscle weakness beginning at 1-4 yr of age. A smaller number of patients may present with fasting hypoketotic hypoglycemia in the 1st yr of life before the cardiomyopathy becomes symptomatic. The underlying defect involves the plasma membrane sodium gradient-dependent carnitine transporter that is present in heart, muscle, and kidney. This transporter is responsible both for maintaining intracellular carnitine concentrations 20- to 50-fold higher than plasma concentrations and for renal conservation of carnitine.

Diagnosis of the carnitine transporter defect is aided by the fact that patients have extremely reduced carnitine levels in plasma and muscle (1-2% of normal). Heterozygote parents have plasma carnitine levels approximately 50% of normal. Fasting ketogenesis may be normal because liver carnitine transport is normal, but it may be impaired if dietary carnitine intake is interrupted. The fasting urinary organic acid profile may show a hypoketotic dicarboxylic aciduria pattern if hepatic fatty acid oxidation is impaired, but it is otherwise unremarkable. The defect in carnitine transport can be demonstrated clinically by severe reduction in renal carnitine threshold or in vitro by assay of carnitine uptake using cultured fibroblasts or lymphoblasts. Mutations in the organic cation/carnitine transporter (OCTN2) underlie this disorder. Treatment of this disorder with pharmacologic doses of oral carnitine (100-200 mg/kg/day) is highly effective in correcting the cardiomyopathy and muscle weakness as well as any impairment in fasting ketogenesis. Muscle total carnitine concentrations remain <5% of normal on treatment.

Carnitine Palmitoyltransferase-IA (CPT-IA) Deficiency

Several dozen infants and children have been described with a deficiency of the liver and kidney isozyme of CPT-IA. Clinical manifestations include fasting hypoketotic hypoglycemia, occasionally with markedly abnormal liver function tests and, rarely, with renal tubular acidosis. The heart and skeletal muscle are not involved because the muscle isozyme is unaffected. Fasting urinary organic acid profile shows a hypoketotic C6-C12 dicarboxylic aciduria but may be normal. Plasma acylcarnitine analysis demonstrates mostly free carnitine with very little acylated carnitine. This observation has been used to establish CPT-IA diagnosis on newborn screening by tandem mass spectrometry. CPT-IA deficiency is the only fatty acid oxidation disorder in which plasma total carnitine levels are elevated to 150-200% of normal. This may be explained by the fact that the inhibitory effects of long-chain acylcarnitines on the renal tubular carnitine transporter are absent in CPT-IA deficiency. The enzyme defect can be demonstrated in cultured fibroblasts or lymphoblasts. CPT-IA deficiency in the fetus has been associated with acute fatty liver of pregnancy in the mother in a single case report. A common variant in the CPT1A gene has been identified in individuals of Inuit background in the USA and First Nations tribes in Canada. The variant results in a positive newborn screen and 20% residual enzyme activity which is unregulated. It has not been established if this is a pathological DNA variant or an adaptive process to ancient Inuit and First Nations lifestyles. Treatment for the severe CPT1A deficiency is similar to that for MCAD deficiency with avoidance of situations where fasting ketogenesis is necessary.

Carnitine Palmitoyltransferase-II (CPT-II) Deficiency

Three forms of CPT-II deficiency have been described. The antenatal presentation of this disorder is associated with a profound enzyme deficiency, and neonatal death has been reported in several newborns with dysplastic kidneys, cerebral malformations, and mild facial anomalies. A severe deficiency of enzyme activity is associated with an infantile-onset form. This form shares all the clinical and laboratory features of CACT deficiency. A milder defect is associated with an adult presentation of episodic rhabdomyolysis. The 1st episode usually does not occur until late childhood or early adulthood. Attacks may be precipitated by prolonged exercise. There is aching muscle pain and myoglobinuria that may be severe enough to cause renal failure. Serum levels of creatine kinase are elevated to 5,000-100,000 U/L. Fasting hypoglycemia has not been described, but fasting may contribute to attacks of myoglobinuria. Muscle biopsy shows increased deposition of neutral fat. The myopathic presentation of CPT-II deficiency is associated with a common mutation S113L. This mutation produces a heat-labile protein that is unstable to increased muscle temperature due to exercise resulting in the myopathic presentation. An intermediate form of CPT-II deficiency presents in infancy/early childhood with fasting-induced hepatic failure, cardiomyopathy, and skeletal myopathy with hypoketotic hypoglycemia but does not have the severe developmental changes seen in the neonatal presentation. This pattern is more like that seen in VLCAD deficiency and management is identical. Patients are generally heterozygous for one of the severe mutations and one of the milder mutations.

Diagnosis of all forms of CPT-II deficiency can be made by demonstrating deficient enzyme activity in muscle or other tissues and in cultured fibroblasts. Mutation analysis is available.

Defects in Electron Transfer Pathway

Electron Transfer Flavoprotein (ETF) and Electron Transfer Flavoprotein Dehydrogenase (ETF-DH) Deficiencies (GLUTARIC Aciduria Type 2, Multiple Acyl CoA Dehydrogenation Deficiencies)

ETF and ETF-DH function to transfer electrons into the mitochondrial electron transport chain from dehydrogenation reactions catalyzed by VLCAD, MCAD, and SCAD, as well as glutaryl CoA dehydrogenase and at least four enzymes involved in branch-chain amino acid oxidation. Deficiencies of ETF or ETF-DH produce illness that combines the features of impaired fatty acid oxidation and impaired oxidation of several amino acids. Complete deficiencies of either protein are associated with severe illness in the newborn period, characterized by acidosis, hypoglycemia, coma, hypotonia, cardiomyopathy, and an unusual odor of sweaty feet due to isovaleryl CoA dehydrogenase inhibition. Some affected neonates have had facial dysmorphism and polycystic kidneys similar to that seen in severe CPT-II deficiency, which suggests that toxic effects of accumulated metabolites may occur in utero.

Diagnosis can be made from the urinary organic acid profile, which shows abnormalities corresponding to blocks in oxidation of fatty acids (ethylmalonate and C6-C10 dicarboxylic acids), lysine (glutarate), and branched-chain amino acids (isovaleryl-, isobutyryl-, and α-methylbutyryl-glycine). Most severely affected infants do not survive the neonatal period.

Partial deficiencies of ETF and ETF-DH produce a disorder that may mimic MCAD deficiency or other milder fatty acid oxidation defects. These patients have attacks of fasting hypoketotic coma. The urinary organic acid profile reveals primarily elevations of dicarboxylic acids and ethylmalonate, derived from short-chain fatty acid intermediates. Secondary carnitine deficiency is present. Some patients with mild forms of ETF/ETF-DH deficiency benefit from treatment with high doses of riboflavin, which is a cofactor for the pathway of electron transfer.

Bibliography

De Leon DD, Stanley CA. Mechanisms of disease: advances in diagnosis and treatment of hyperinsulinism in neonates. Nat Clin Pract Endocrinol Metab. 2007;3:57-68.

Gillingham MB, Weleber RG, Neuringer M, et al. Effect of optimal dietary therapy upon visual function in children with long-chain 3-hydroxyacyl CoA dehydrogenase and trifunctional protein deficiency. Mol Genet Metab. 2005;86:124-133.

Greenberg CR, Dilling LA, Thompson GR, et al. The paradox of the carnitine palmitoyltransferase type 1a P479L variant in Canadian Aboriginal populations. Mol Genet Metab. 2009;96:201-207.

Hsu HW, Zytkovicz TH, Comeau AM, et al. Spectrum of medium-chain acyl-CoA dehydrogenase deficiency detected by newborn screening. Pediatrics. 2008;121:e1108-e1114.

Jethva R, Bennett MJ, Vockley J. Short-chain acyl-coenzyme A dehydrogenase deficiency. Mol Genet Metab. 2008;95:195-200.

Longo N, di San Filippo CA, Pasquali M. Disorders of carnitine transport and the carnitine cycle. Am J Med Genet C Semin Med Genet. 2006;142C:77-85.

Loughrey C, Bennett MJ. Screening for MCAD deficiency in newborns. BMJ. 2009;338:843-846.

Molven A, Matre GE, Duran M, et al. Familial hyperinsulinemic hypoglycemia caused by a defect in the SCHAD enzyme of mitochondrial fatty acid oxidation. Diabetes. 2004;53:221-227.

Schulze A, Matern D, Hoffmann GF. Newborn Screening. In: Sarafoglou K, Hoffmann GF, Roth KS, editors. Pediatric endocrinology and inborn errors of metabolism. New York: McGraw-Hill; 2009:17-32.

Shekhawat PS, Matern D, Strauss AW. Fetal fatty acid oxidation disorders, their effect on maternal health and neonatal outcome: impact of expanded newborn screening on their diagnosis and management. Pediatr Res. 2005;57:78R-86R.

Strauss AW, Andresen BS, Bennett MJ. Mitochondrial fatty acid oxidation defects. In: Sarafoglou K, Hoffmann GF, Roth KS, editors. Pediatric endocrinology and inborn errors of metabolism. New York: McGraw-Hill; 2009:51-70.

van Maldegem BT, Duran M, Wanders RJA, et al. Fasting and fat-loading tests provide pathophysiological insight into short-chain acyl-coenzyme A dehydrogenase deficiency. J Pediatr. 2010;156:121-127.

Wilcken B, Haas M, Joy P, et al. Outcome of neonatal screening for medium-chain acyl-CoA dehydrogenase deficiency in Australia: a cohort study. Lancet. 2007;369:37-42.

80.2 Disorders of Very Long Chain Fatty Acids

Peroxisomal Disorders

The peroxisomal diseases are genetically determined disorders caused either by the failure to form or maintain the peroxisome or by a defect in the function of a single enzyme that is normally located in this organelle. These disorders cause serious disability in childhood and occur more frequently and present a wider range of phenotype than has been recognized in the past.

Etiology

Peroxisomal disorders are subdivided into 2 major categories (Table 80-2).

Table 80-2 CLASSIFICATION OF PEROXISOMAL DISORDERS

A: DISORDERS OF PEROXISOME IMPORT

A1: Zellweger syndrome

A2: Neonatal adrenoleukodystrophy

A3: Infantile Refsum disease

A4: Rhizomelic chondrodysplasia punctata

B: DEFECTS OF SINGLE PEROXISOMAL ENZYME

B1: X-linked adrenoleukodystrophy

B2: Acyl CoA oxidase deficiency

B3: Bifunctional enzyme deficiency

B4: Peroxisomal thiolase deficiency

B5: Classic Refsum disease

B6: 2-Methylacyl CoA racemase deficiency

B7: DHAP acyltransferase deficiency

B8: Alkyl-DHAP synthase deficiency

B9: Mevalonic aciduria

B10: Glutaric aciduria type III

B11: Hyperoxaluria type I

B12: Acatalasemia

In category A, the peroxisomal biogenesis disorders (PBD), the basic defect is the failure to import one or more proteins into the organelle. In category B, defects affect a single peroxisomal protein. The peroxisome is present in all cells except mature erythrocytes and is a subcellular organelle surrounded by a single membrane; >50 peroxisomal enzymes are identified. Some enzymes are involved in the production and decomposition of hydrogen peroxide; others are concerned with lipid and amino acid metabolism. Most peroxisomal enzymes are first synthesized in their mature form on free polyribosomes and enter the cytoplasm. Proteins that are destined for the peroxisome contain specific peroxisome targeting sequences (PTS). Most peroxisomal matrix proteins contain PTS1, a 3-amino acid sequence at the carboxyl terminus. PTS2 is an amino-terminal sequence that is critical for the import of enzymes involved in plasmalogen and branched-chain fatty acid metabolism. Import of proteins involves a complex series of reactions that involves at least 23 distinct proteins. These proteins are referred to as peroxins encoded by PEX genes. Table 80-3 summarizes the PEX genes that are defective in human disease states.

Epidemiology

Except for X-linked adrenoleukodystrophy (X-ALD), all the peroxisomal disorders in Table 80-2 are autosomal recessive traits. X-ALD is the most common peroxisomal disorder, with an estimated incidence of 1/17,000. The combined incidence of the other peroxisomal disorders is estimated to be 1/50,000.

Pathogenesis

It is likely that all pathologic changes are secondary to the peroxisome defect. Multiple peroxisomal enzymes fail to function in the PBD (Table 80-4). The enzymes that are diminished or absent are synthesized but are degraded abnormally fast because they may be unprotected outside of the peroxisome. It is not clear how defective peroxisome functions lead to the widespread pathologic manifestations.

Table 80-4 ABNORMAL LABORATORY FINDINGS COMMON TO DISORDERS OF PEROXISOME BIOGENESIS

Peroxisomes absent to reduced in number

Catalase in cytosol

Deficient synthesis and reduced tissue levels of plasmalogens

Defective oxidation and abnormal accumulation of very long chain fatty acids

Deficient oxidation and age-dependent accumulation of phytanic acid

Defects in certain steps of bile acid formation and accumulation of bile acid intermediates

Defects in oxidation and accumulation of L-pipecolic acid

Increased urinary excretion of dicarboxylic acids

The PBD are associated with genetically determined import defects. The PBD have been subdivided into 12 complementation groups. The molecular defects have been defined in 10 of these groups (see Table 80-3). The pattern and severity of pathologic features vary with the nature of the import defects and the degree to which import is impaired. These gene defects lead to disorders that were named before their relationship to the peroxisome was recognized, namely, Zellweger syndrome (ZS), neonatal adrenoleukodystrophy (NALD), infantile Refsum disease (IRD), and rhizomelic chondrodysplasia punctata (RCDP). The first 3 disorders are considered to form a clinical continuum, with ZS the most severe, IRD the least severe, and NALD intermediate. They can be caused by 11 different gene defects, which involve mainly the import of proteins that contain the PTS1 targeting signal; the gene defects cannot be distinguished on the basis of clinical features. The clinical severity varies with the degree to which protein import is impaired. Mutations that abolish import completely are often associated with the ZS phenotype, whereas a missense mutation, in which some degree of import function is retained, leads to the somewhat milder phenotypes. A defect in PEX7, which involves the import of proteins that utilize PTS2, is associated with RCDP. PEX7 defects that leave import partially intact are associated with milder phenotypes, some of which resemble classic Refsum disease.

The genetic disorders that involve single peroxisomal enzymes usually have clinical manifestations that are more restricted and present subsequent to the neonatal period and not infrequently in adolescents or adults. The clinical manifestations may be related to the biochemical defect. The primary adrenal insufficiency of X-ALD is caused by accumulation of very long chain fatty acids (VLCFA) in the adrenal cortex, and the peripheral neuropathy in Refsum disease is caused by the accumulation of phytanic acid in Schwann cells and myelin.

PBD With Milder or Atypical Phenotypes

Newborn infants with Zellweger syndrome show striking and consistent, recognizable abnormalities. Of central diagnostic importance are the typical facial appearance (high forehead, unslanting palpebral fissures, hypoplastic supraorbital ridges, and epicanthal folds; Fig. 80-3), severe weakness and hypotonia, neonatal seizures, and eye abnormalities (cataracts, glaucoma, corneal clouding, Brushfield spots, pigmentary retinopathy, and nerve dysplasia). Because of the hypotonia and “mongoloid” appearance, Down syndrome may be suspected. Infants with Zellweger syndrome rarely live more than a few months. More than 90% show postnatal growth failure. Table 80-5 lists the main clinical abnormalities.

Patients with neonatal ALD show fewer and, occasionally, no dysmorphic features. Neonatal seizures occur frequently. Some degree of psychomotor development is present; function remains in the severely or profoundly retarded range, and development may regress after 3-5 yr of age, probably from a progressive leukodystrophy. Several patients are now in a stable, albeit disabled, state in their 3rd or 4th decade. Hepatomegaly, impaired liver function, pigmentary degeneration of the retina, and severely impaired hearing are invariably present. Adrenocortical function is usually impaired, but overt Addison disease is rare. Chondrodysplasia punctata and renal cysts are absent.

Patients with infantile Refsum disease have survived to the 2nd decade or longer. They are able to walk, although gait may be ataxic and broad based. Cognitive function is in the severely retarded range. All have sensorineural hearing loss and pigmentary degeneration of the retina. They have moderately dysmorphic features that may include epicanthal folds, a flat bridge of the nose, and low-set ears. Early hypotonia and hepatomegaly with impaired function are common. Levels of plasma cholesterol and high- and low-density lipoprotein are often moderately reduced. Chondrodysplasia punctata and renal cortical cysts are absent. Postmortem study in infantile Refsum disease reveals micronodular liver cirrhosis and small hypoplastic adrenals. The brain shows no malformations, except for severe hypoplasia of the cerebellar granule layer and ectopic locations of the Purkinje cells in the molecular layer. The mode of inheritance is autosomal recessive.

Some patients with PBD disorders have milder and atypical phenotypes. They may present with peripheral neuropathy or with retinopathy, impaired vision, or cataracts in childhood, adolescence, or adulthood and have been diagnosed to have Charcot-Marie-Tooth disease or Usher syndrome. Some patients have survived to the 5th decade. Defects in PEX7, which most commonly lead to the RCDP phenotype, may also lead to a milder phenotype with clinical manifestations similar to those of classical Refsum disease (phytanoyl CoA hydroxylase deficiency).

Isolated Defects of Peroxisomal Fatty Acid Oxidation

The disorders labeled B1 through B3 (see Table 80-2) each involve 1 of 3 enzymes involved in peroxisomal fatty acid oxidation. Their clinical manifestations resemble those of the Zellweger syndrome/neonatal ALD/infantile Refsum disease continuum; they can be distinguished from disorders of peroxisome biogenesis by laboratory tests. Defects of bifunctional enzyme are common and are found in about 15% of patients with the Zellweger syndrome/neonatal ALD/infantile Refsum disease phenotype. Patients with isolated acyl CoA oxidase deficiency have a somewhat milder phenotype that resembles that of neonatal ALD.

Isolated Defects of Plasmalogen Synthesis

Plasmalogens are lipids in which the 1st carbon of glycerol is linked to an alcohol rather than a fatty acid. They are synthesized through a complex series of reactions, the 1st two steps of which are catalyzed by the peroxisomal enzymes dihydroxyacetone phosphate alkyl transferase and synthase. Deficiency of either of these enzymes (B4 and B5 in Table 80-2) leads to a phenotype that is clinically indistinguishable from the peroxisomal import disorder RCDP. This latter disorder is caused by a defect in PEX7, the receptor for peroxisome targeting sequence 2. It shares the severe deficiency of plasmalogens with disorders B4 and B5 but, in addition, has defects of phytanic oxidation. The fact that disorders B4 and B5 are associated with the full phenotype of RCDP suggests that a deficiency of plasmalogens is sufficient to produce it.

Laboratory Findings

Laboratory tests for peroxisomal disorders can be viewed at three levels of complexity.

Level 1: Does the Patient have a Peroxisomal Disorder?

This can be resolved by noninvasive tests that are generally available (Table 80-6). Measurement of plasma VLCFA is the most commonly used assay. Whereas plasma VLCFA levels are elevated in many patients with peroxisomal disorders, this is not always the case. The most important exceptions are RCDP, in which VLCFA levels are normal, but plasma phytanic acid levels are increased and red blood cell plasmalogen levels are reduced. In some other peroxisomal disorders, the biochemical abnormalities are still more restricted. Therefore, a panel of tests is recommended and includes plasma levels of VLCFA and phytanic, pristanic, and pipecolic acids and red blood cell levels of plasmalogens. Tandem mass spectrometry techniques also permit convenient quantitation of bile acids in plasma and urine. This panel of tests can be performed on 2 mL samples of venous blood and permits detection of most peroxisomal disorders. Furthermore, normal results make the presence of a peroxisomal disorder unlikely.

Level 2: What is the Precise Nature of the Peroxisomal Disorder?

Table 80-6 lists the main biochemical abnormalities in the various peroxisomal disorders. When combined with the clinical presentation, the panel of level 1 tests (see earlier) is often sufficient to identify the precise nature of the defect. Elevated plasma VLCFA levels permit the precise diagnosis of X-ALD in male patients. Marked reduction of erythrocyte plasmalogen levels combined with elevated plasma phytanic acid permits precise diagnosis in a patient with the clinical features of RCDP. Classic Refsum disease can be diagnosed by demonstration of increased plasma phytanic acid combined with normal or reduced levels of pristanic acid levels, while in D-bifunctional enzyme deficiency and 2-methylacyl CoA racemase deficiency, the levels of pristanic and phytanic acid are both increased. Precise identification of some peroxisomal disorders may require more extensive studies in cultured skin fibroblasts. This may be required for the differentiation of PBD from defects in bifunctional enzyme. In PBD, the patient’s peroxisomes are absent and catalase is in the soluble fraction, whereas in bifunctional enzyme defect, peroxisomes are present and catalase is in the particulate fraction. Fibroblast studies are required to identify the nature of the molecular defect in PBD. Whether such specialized studies are clinically warranted depends on individual circumstances. Precise definition of the defect in a proband may improve the precision of prenatal diagnosis in at-risk pregnancies, and it is required for carrier detection. It is also of value in setting prognosis. Precise characterization is of prognostic value in patients with PEX1 defects. This defect is present in approximately 60% of PBD patients, and about half of the PEX1 defects have the G843D allele, which is associated with a significantly milder phenotype than is found in other mutations.

Level 3: What is the Molecular Defect?

Table 80-3 shows that the molecular defects in most of the PBD have been defined. Definition of the molecular defect in the proband, which is now offered in several laboratories, is essential for carrier detection and speeds prenatal diagnosis.

Diagnosis

There are several noninvasive laboratory tests that permit precise and early diagnosis of peroxisomal disorders (see Table 80-6). The challenge in PBD is to differentiate them from the large variety of other conditions that can cause hypotonia, seizures, failure to thrive, or dysmorphic features. Experienced clinicians can readily recognize classic Zellweger syndrome by its clinical manifestations. PBD patients often do not show the full clinical spectrum of disease and may be identifiable only by laboratory assays. Clinical features that may serve as indications for these diagnostic assays include severe psychomotor retardation; weakness and hypotonia; dysmorphic features; neonatal seizures; retinopathy, glaucoma, or cataracts; hearing deficits; enlarged liver and impaired liver function; and chondrodysplasia punctata. The presence of one or more of these abnormalities increases the likelihood of this diagnosis. Atypical milder forms presenting as peripheral neuropathy have also been described.

Some patients with the isolated defects of peroxisomal fatty acid oxidation (group B) resemble those with group A disorders and can be detected by the demonstration of abnormally high levels of VLCFA.

Patients with RCDP must be distinguished from patients with other causes of chondrodysplasia punctata. In addition to warfarin embryopathy and Zellweger syndrome, these disorders include the milder autosomal dominant form of chondrodysplasia punctata (Conradi-Hünermann syndrome), which is characterized by longer survival, absence of severe limb shortening, and usually intact intellect; an X-linked dominant form; and an X-linked recessive form associated with a deletion of the terminal portion of the short arm of the X chromosome. RCDP is suspected clinically because of the shortness of limbs, psychomotor retardation, and ichthyosis. The most decisive laboratory test is the demonstration of abnormally low plasmalogen levels in red blood cells and an impaired capacity to synthesize plasmalogens in cultured skin fibroblasts. These biochemical defects are not present in other types of chondrodysplasia punctata. Chondrodysplasia punctata may also be associated with a defect of 3β-hydroxysteroid-Δ87-isomerase, an enzyme involved in biosynthesis of cholesterol.

Genetic Counseling

All the peroxisomal disorders, except hyperoxaluria type 1, can be diagnosed prenatally in the 1st or 2nd trimester. The tests are similar to those described for postnatal diagnosis (see Table 80-6) and use chorionic villus sampling or amniocytes. More than 300 pregnancies have been monitored, and more than 60 affected fetuses have been identified without diagnostic error. Because of the 25% recurrence risk, couples with an affected child must be advised about the availability of prenatal diagnosis. Heterozygotes can be identified in X-ALD and in those disorders in which the molecular defect has been identified (see Table 80-3).

Adrenoleukodystrophy (X-Linked)

X-ALD is a genetically determined disorder associated with the accumulation of saturated VLCFA and a progressive dysfunction of the adrenal cortex and central and peripheral nervous system white matter.

Clinical Manifestations

There are 5 relatively distinct phenotypes, 3 of which are present in childhood with symptoms and signs. In all the phenotypes, development is usually normal in the 1st 3-4 yr of life.

In the childhood cerebral form of ALD, symptoms are first noted most commonly between the ages of 4 and 8 yr (21 mo is the earliest onset reported). The most common initial manifestations are hyperactivity, which is often mistaken for an attention deficit disorder, and worsening school performance in a child who had previously been a good student. Auditory discrimination is often impaired, although tone perception is preserved. This may be evidenced by difficulty in using the telephone and greatly impaired performance on intelligence tests in items that are presented verbally. Spatial orientation is often impaired. Other initial symptoms are disturbances of vision, ataxia, poor handwriting, seizures, and strabismus. Visual disturbances are often due to involvement of the cerebral cortex, which leads to variable and seemingly inconsistent visual capacity. Seizures occur in nearly all patients and may represent the 1st manifestation of the disease. Some patients present with increased intracranial pressure or with unilateral mass lesions. Impaired cortisol response to ACTH stimulation is present in 85% of patients, and mild hyperpigmentation is noted. In most patients with this phenotype, adrenal dysfunction is recognized only after the condition is diagnosed because of the cerebral symptoms. Cerebral childhood ALD tends to progress rapidly with increasing spasticity and paralysis, visual and hearing loss, and loss of ability to speak or swallow. The mean interval between the 1st neurologic symptom and an apparently vegetative state is 1.9 yr. Patients may continue in this apparently vegetative state for 10 yr or more.

Adolescent ALD designates patients who experience neurologic symptoms between the ages of 10 and 21 yr. The manifestations resemble those of childhood cerebral ALD except that progression is slower. About 10% of patients present acutely with status epilepticus, adrenal crisis, acute encephalopathy, or coma.

Adrenomyeloneuropathy first manifests in late adolescence or adulthood as a progressive paraparesis caused by long tract degeneration in the spinal cord. Approximately half of the patients also have involvement of the cerebral white matter.

The “Addison only” phenotype is an important and underdiagnosed condition. Of male patients with Addison disease, 25% may have the biochemical defect of ALD. Many of these patients have intact neurologic systems, whereas others have subtle neurologic signs. Many acquire adrenomyeloneuropathy in adulthood.

The term “asymptomatic ALD” is applied to persons who have the biochemical defect of ALD but are free of neurologic or endocrine disturbances. Nearly all persons with the gene defect eventually become neurologically symptomatic. A few have remained asymptomatic even in the 6th or 7th decade.

Approximately 50% of female heterozygotes acquire a syndrome that resembles adrenomyeloneuropathy but is milder and of later onset. Adrenal insufficiency is rare.

Laboratory and Radiographic Findings

The most specific and important laboratory finding is the demonstration of abnormally high levels of VLCFA in plasma, red blood cells, or cultured skin fibroblasts. The test should be performed in a laboratory that has experience with this specialized procedure. Positive results are obtained in all male patients with X-ALD and in about 85% of female carriers of X-ALD. Mutation analysis is the most reliable method for the identification of carriers.

CT And MRI

Patients with childhood cerebral or adolescent ALD show cerebral white matter lesions that are characteristic with respect to location and attenuation patterns on MRI. In 80% of patients, the lesions are symmetric and involve the periventricular white matter in the posterior parietal and occipital lobes. About 50% show location of a garland of accumulated contrast material adjacent and anterior to the posterior hypodense lesions (Fig. 80-5A). This zone corresponds to the zones of intense perivascular lymphocytic infiltration where the blood-brain barrier breaks down. In 12% of patients, the initial lesions are frontal. Unilateral lesions that produce a mass effect suggestive of a brain tumor may occur. MRI provides a clearer delineation of normal and abnormal white matter than does CT and may demonstrate abnormalities missed by CT (Fig. 80-5B).

Diagnosis and Differential Diagnosis

The earliest manifestations of childhood cerebral ALD are difficult to distinguish from the more common attention-deficit disorders or learning disabilities. Rapid progression, signs of dementia, or difficulty in auditory discrimination suggest ALD. Even in early stages, CT or MRI may show strikingly abnormal changes. Other leukodystrophies (Chapters 592 and 605.10) or multiple sclerosis (Chapter 593.1) may mimic these radiographic findings. Definitive diagnosis depends on demonstration of VLCFA excess, which occurs only in X-ALD and the other peroxisomal disorders. The latter may be distinguished from X-ALD by their clinical presentation during the neonatal period.

Cerebral forms of ALD may present as increased intracranial pressure and unilateral mass lesions. These have been misdiagnosed as gliomas, even after brain biopsy, and several patients have received radiotherapy before the correct diagnosis was made. Measurement of VLCFA in plasma or brain biopsy specimens is the most reliable differentiating test.

Adolescent or adult cerebral ALD can be confused with psychiatric disorders, dementing disorders, or epilepsy. The 1st clue to the diagnosis of ALD may be the demonstration of white matter lesions by CT or MRI; assays of VLCFA are confirmatory.

ALD cannot be distinguished clinically from other forms of Addison disease; it is recommended that assays of VLCFA levels be performed in all male patients with Addison disease. ALD patients do not usually have antibodies to adrenal tissue in their plasma.

Treatment

Corticosteroid replacement for adrenal insufficiency or adrenocortical hypofunction is effective (Chapter 569). It may be lifesaving and increase general strength and well-being, but it does not alter the course of the neurologic disability.

Bone Marrow Transplantation

Bone marrow transplantation (BMT) benefits patients who show early evidence of the inflammatory demyelination that is characteristic of the rapidly progressive neurologic disability in boys and adolescents with the cerebral X-ALD phenotype. BMT is a high-risk procedure, and patients must be selected with great care. The mechanism of the beneficial effect is incompletely understood. Bone marrow-derived cells do express ALDP, the protein that is deficient in X-ALD; approximately 50% of brain microglial cells are bone marrow derived. It is possible that replacement of affected cells by cells that contain the normal gene changes the brain milieu sufficiently to correct the brain metabolic disturbance. The favorable effect may also be caused by modification of the brain inflammatory response. Five to 10 yr follow-up of boys and adolescents who had early cerebral involvement has shown stabilization and, in some instances, improvement. On the other hand, BMT has not shown favorable effects in patients who had already severe brain involvement and may accelerate disease progression under these circumstances. The nonverbal IQ has been found to be of predictive value, and transplant is not recommended in patients with nonverbal IQ significantly below 80. Unfortunately, in more than half the patients who are diagnosed because of neurologic symptoms, the illness is so advanced that they are not candidates for transplant.

Consideration of BMT is most relevant in neurologically asymptomatic or mildly involved patients. Screening at-risk relatives of symptomatic patients identifies these patients most frequently. Screening by measurement of plasma VLCFA levels in patients with Addison disease may also identify candidates for BMT. Because of its risk (10-20% mortality) and the fact that up to 50% of untreated patients with X-ALD do not develop inflammatory brain demyelination, transplant is not recommended in patients who are free of demonstrable brain involvement. The MRI is also of key importance for the crucial decision of whether transplant should be performed. MRI abnormalities precede clinically evident neurologic or neuropsychologic abnormalities. The brain MRI should be monitored at 6 mo to 1 yr intervals in neurologically asymptomatic boys and adolescents between the ages of 3 and 15 yr. If the MRI is normal, BMT is not indicated. If brain MRI abnormalities develop, the patient should be evaluated at 3 mo intervals to determine if the abnormality is progressive, in combination with careful neurologic and neuropsychologic evaluation; and if early progressive involvement is confirmed, transplant should be considered. Magnetic resonance spectroscopy improves the capacity to determine whether the brain involvement is progressive. It is not known whether BMT has a favorable effect on the noninflammatory spinal cord involvement in adults with the adrenomyeloneuropathy phenotype.

Supportive Therapy

The progressive behavioral and neurologic disturbances associated with the childhood form of ALD are extremely difficult for the family. ALD patients require the establishment of a comprehensive management program and partnership among the family, physician, visiting nursing staff, school authorities, and counselors. In addition, parent support groups are often helpful (United Leukodystrophy Foundation, 2304 Highland Drive, Sycamore, IL 60178). Communication with school authorities is important because under the provisions of Public Law 94-142, children with ALD qualify for special services as “other health impaired” or “multihandicapped.” Depending on the rate of progression of the disease, special needs might range from relatively low-level resource services within a regular school program to home- and hospital-based teaching programs for children who are not mobile.

Management challenges vary with the stage of the illness. The early stages are characterized by subtle changes in affect, behavior, and attention span. Counseling and communication with school authorities are of prime importance. Changes in the sleep-wake cycle can be benefited by the judicious use at night of sedatives such as chloral hydrate (10-50 mg/kg), pentobarbital (5 mg/kg), or diphenhydramine (2-3 mg/kg).

As the leukodystrophy progresses, the modulation of muscle tone and support of bulbar muscular function are major concerns. Baclofen in gradually increasing doses (5 mg bid to 25 mg qd) is the most effective pharmacologic agent for the treatment of acute episodic painful muscle spasms. Other agents may also be used, with care being taken to monitor the occurrence of side effects and drug interactions. As the leukodystrophy progresses, bulbar muscular control is lost. Although initially this can be managed by changing the diet to soft and pureed foods, most patients eventually require a nasogastric tube or a gastrostomy. At least 30% of patients have focal or generalized seizures that usually readily respond to standard anticonvulsant medications.

Genetic Counseling and Prevention

Genetic counseling and primary and secondary prevention of X-ALD are of crucial importance. Extended family screening should be offered to all at-risk relatives of symptomatic patients; one program led to the identification of more than 250 asymptomatic affected males and 1,200 women heterozygous for X-ALD. The plasma assay permits reliable identification of affected males in whom plasma VLCFA levels are increased already on the day of birth. Identification of asymptomatic males permits institution of steroid replacement therapy when appropriate and prevents the occurrence of adrenal crisis, which may be fatal. Monitoring of brain MRI also permits identification of patients who are candidates for BMT at a stage when this procedure has the greatest chance of success. Plasma VLCFA assay is recommended in all male patients with Addison disease. X-ALD has been shown to be the cause of adrenal insufficiency in >25% of boys with Addison disease of unknown cause. Identification of women heterozygous for X-ALD is more difficult than that of affected males. Plasma VLCFA levels are normal in 15-20% of heterozygous women, and failure to note this has led to serious errors in genetic counseling. If VLCFA levels are normal both in plasma and cultured skin fibroblasts, the risk of false-negative results is reduced but not eliminated. DNA analysis permits accurate identification of carriers, provided that the mutation has been defined in a family member, and is the procedure recommended for the identification of heterozygous women. Mutation analysis is available on a service basis.

Prenatal diagnosis of affected male fetuses can be achieved by measurement of VLCFA levels in cultured amniocytes or chorionic villus cells and by mutation analysis. Whenever a new patient with X-ALD is identified, a detailed pedigree should be constructed and efforts should be made to identify all at-risk female carriers and affected males. These investigations should be accompanied by careful and sympathetic attention to social, emotional, and ethical issues during counseling.

Bibliography

Peroxisomal Disorders

Ferdinandusse S, Ylianttila MS, Gloerich J, et al. Mutational spectrum of D-bifunctional protein deficiency and structure-based genotype-phenotype analysis. Am J Hum Genet. 2006;78:112-124.

Fidaleo M. Peroxisomes and peroxisomal disorders: the main facts. Exp Toxicol Pathol. 2009 Sep 7. Epub ahead of print

Moser HW. Genotype-phenotype correlations in disorders of peroxisome biogenesis. Mol Genet Metab. 1999;68:316-327.

Motley AM, Brites P, Gerez L, et al. Mutational spectrum in the PEX7 gene and functional analysis of mutant alleles in 78 patients with rhizomelic chondrodysplasia punctata type 1. Am J Hum Genet. 2002;70:612-624.

Steinberg S, Chen L, Wei L, Moser A, et al. The PEX gene screen: Molecular diagnosis of peroxisome biogenesis disorders in the Zellweger syndrome spectrum. Mol Genet Metab. 2004;83:252-263.

Walter C, Gootjes J, Mooijer PA. Disorders of peroxisome biogenesis due to mutations in PEX1: phenotypes and PEX1 protein levels. Am J Hum Genet. 2001;69:35-48.

Wanders RJ, Jansen GA, Skjeldal OH. Refsum disease, peroxisomes and phytanic acid oxidation: a review. J Neuropathol Exp Neurol. 2001;60:1021-1031.

Wanders RJ, Komen JC. Peroxisomes, lipid metabolism, and peroxisomal disorders. Biochem Soc Trans. 2007;35:865-869.

Wanders RJ, Waterham HR. Peroxisomal disorders: the single peroxisomal enzyme deficiencies. Biochim Biophys Acta. 2006;1763:1707-1720.

Waterham HR, Koster J, van Roermund CWT, et al. A lethal defect of mitochondrial and peroxisomal fission. N Engl J Med. 2007;356:1736-1740.

80.3 Disorders of Lipoprotein Metabolism and Transport

Epidemiology of Blood Lipids and Cardiovascular Disease

The relationship between dietary fat consumption and plasma cholesterol was demonstrated nearly a century ago. The Seven Countries Study of geographic, social class, and ethnic differences in coronary heart disease (CHD) around the world found strong associations between average intake of saturated fats, plasma cholesterol, and mortality from CHD. Of all common chronic diseases, none is so clearly influenced by both environmental and genetic factors as CHD. This multifactorial disorder is strongly associated with increasing age and male gender, though it is increasingly apparent that heart disease is under recognized in women. Tobacco use confers a 2-fold higher lifetime risk. Sedentary activity and high intake of saturated fats leading to adiposity increase risk through differences in the plasma levels of lipoproteins that are atherogenic. Family history is a reflection of the combined influence of lifestyle and genetic predisposition to early heart disease. Risk of premature heart disease associated with positive family history is 1.7 times higher than in families with no such history.

The pathogenesis of atherosclerosis begins during childhood. The Johns Hopkins Precursors Study demonstrated that white male medical students with blood cholesterol levels in the lowest quartile showed only a 10% incidence of CHD 3 decades later, whereas those in the highest quartile had a 40% incidence. The Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Study demonstrated a significant relationship between the weight of the abdominal fat pad and the extent of atherosclerosis found at autopsy on subjects 15-34 yr of age. The Bogalusa Heart Study of >3,000 black and white children and adolescents has provided the most comprehensive longitudinal data relating the presence and severity of CHD risk factors with semiquantifiable severity of atherosclerosis.

The “fetal origins hypothesis” is based on the observation that infants born with low birthweight have a higher incidence of heart disease as adults. Epidemiologic studies support the idea that prenatal and early postnatal conditions may affect adult health status. Children who are large for gestational age at birth and exposed to an intrauterine environment of either diabetes or maternal obesity are at increased risk of eventually developing the “metabolic syndrome” (insulin resistance, type II diabetes, obesity, CHD). Breast-feeding preterm infants confers a long-term cardioprotective benefit 13-16 yr later. Those adolescents who were breast-fed as infants had lower C-reactive protein concentrations and a 14% lower LDL to HDL ratio compared to those fed infant formulas.

In addition, secondary causes of hyperlipidemia may be the result of drugs (cyclosporine, steroids, isotretinoin, protease inhibitors, alcohol, thiazide diuretics, beta blocking agents, valproate), or various diseases (nephrotic syndrome, hypothyroidism, Cushing syndrome, anorexia nervosa, obstructive jaundice).

Blood Lipids and Atherogenesis

Numerous epidemiologic studies have demonstrated the association of hypercholesterolemia, referring to elevated total blood cholesterol, with atherosclerotic disease. The ability to measure subcomponents within classes of lipid particles, as well as markers of inflammation, have further elucidated the process of atherogenesis and plaque rupture leading to acute coronary syndromes. Atherosclerosis affects primarily the coronary arteries but also often involves the aorta, arteries of the lower extremities, and carotid arteries.

The early stage of development of atherosclerosis is thought to begin with vascular endothelial dysfunction and intima media thickness, which has been shown to occur in preadolescent children with risk factors such as obesity or familial hypercholesterolemia. The complex process of penetration of the intimal lining of the vessel may be due to a variety of insults, including the presence of highly toxic oxidized LDL particles. Lymphocytes and monocytes penetrate the damaged endothelial lining, where they become macrophages laden with LDL lipids and then become foam cells. Such accumulation is counterbalanced by HDL particles capable of removing lipid deposits from the vessel wall. Fundamental to plaque formation is an inflammatory process (elevated C-reactive protein) involving macrophages and the arterial wall. The deposition of lipid within the subendothelial lining of the arterial wall appears macroscopically as fatty streaks, which may to some degree be reversible. A later stage of plaque development involves disruption of arterial smooth muscle cells stimulated by the release of tissue cytokines and growth factors. The atheroma is composed of a core of fatty substance separated from the lumen by collagen and smooth muscle (Fig. 80-6). Growth of the atherosclerotic plaque may result in ischemia of the tissue supplied by the artery. Chronic inflammation within the atheroma, perhaps caused by infectious agents such as Chlamydia pneumoniae, results in plaque instability and subsequent rupture. Platelet adherence leads to clot formation at the site of rupture, resulting in myocardial infarction or a cerebrovascular event.

Plasma Lipoprotein Metabolism and Transport

Abnormalities of lipoprotein metabolism are associated with diabetes mellitus and premature atherosclerosis. Lipoproteins are soluble complexes of lipids and proteins that effect transport of fat absorbed from the diet, or synthesis by the liver and adipose tissues, for utilization and storage. Dietary fat is transported from the small intestine as chylomicrons. Lipids synthesized by the liver as very low density lipoproteins (VLDL) are catabolized to intermediate density lipoproteins (IDL) and low-density lipoproteins (LDL). High-density lipoproteins (HDL) are fundamentally involved in VLDL and chylomicron metabolism and cholesterol transport. Nonesterified free fatty acids (FFAs) are metabolically active lipids derived from lipolysis of triglycerides stored in adipose tissue bound to albumin for circulation in the plasma (Fig. 80-7).

Lipoproteins consist of a central core of triglycerides and cholesteryl esters (CE) surrounded by phospholipids, cholesterol, and proteins (Fig. 80-8). The density of the several classes of lipoproteins is inversely proportional to the ratio of lipid to protein (Fig. 80-9).

Constituent proteins are known as apolipoproteins (Table 80-7). They are responsible for a variety of metabolic functions in addition to their structural role, including cofactors or inhibitors of enzymatic pathways, and mediators of lipoprotein binding to cell surface receptors. ApoA is the major apoliprotein of HDL. ApoB is present in LDL, VLDL, IDL, and chylomicrons. ApoB-100 is derived from the liver, whereas apoB-48 comes from the small intestine. ApoC-I, C-II, and C-III are small peptides important in triglyceride metabolism. Likewise, apoE, which is present in VLDL, HDL, chylomicrons, and chylomicron remnants, plays an important role in the clearance of triglycerides.

Transport of Exogenous (Dietary) Lipids

All dietary fat with the exception of medium-chain triglycerides is efficiently carried into the circulation by way of lymphatic drainage from the intestinal mucosa. Triglyceride (TG) and CE combine with apoA and apoB-48 in the intestinal mucosa to form chylomicrons, which are carried into the peripheral circulation via the lymphatic system. HDL particles contribute apoC-II to the chylomicrons, required for the activation of lipoprotein lipase (LPL) within the capillary endothelium of adipose, heart, and skeletal muscle tissue. Free fatty acids are oxidized, resterified for storage as triglycerides, or released into the circulation bound to albumin for transport to the liver. After hydrolysis of the TG core from the chylomicron, apoC particles are recirculated back to HDL. The subsequent contribution of apoE from HDL to the remnant chylomicron facilitates binding of the particle to hepatic LDL receptors (LDL-R). Within the hepatocyte, the chylomicron remnant may be incorporated into membranes, re-secreted as lipoprotein back into the circulation, or secreted as bile acids. Normally, all dietary fat is disposed of within 8 hr after the last meal, an exception being individuals with a disorder of chylomicron metabolism. Postprandial hyperlipidemia is a risk factor for atherosclerosis. Abnormal transport of chylomicrons and their remnants may result in their absorption into the blood vessel wall as foam cells, caused by the ingestion of CE by macrophages, the earliest stage in the development of fatty streaks.

Transport of Endogenous Lipids from the Liver

The formation and secretion of VLDL from the liver and its catabolism to IDL and LDL particles describe the endogenous lipoprotein pathway. Fatty acids used in the hepatic formation of VLDL are derived primarily by uptake from the circulation. VLDL appears to be transported from the liver as rapidly as it is synthesized, and it consists of triglycerides, cholesteryl esters, phospholipids, and apoB-100. Nascent particles of VLDL secreted into the circulation combine with apoliproteins Cs and E. The size of the VLDL particle is determined by the amount of triglyceride present, progressively shrinking in size as TG is hydrolyzed by the action of LPL, yielding free fatty acids for utilization or storage in muscle and adipose tissue. Hydrolysis of about 80% of the TG present in VLDL particles produces IDL particles containing an equal amount of cholesterol and TG. The remaining remnant IDL is converted to LDL for delivery to peripheral tissues or to the liver. ApoE is attached to the remnant IDL particle to allow binding to the cell and subsequent incorporation into the lysosome. Individuals with deficiency of either apoE2 or hepatic triglyceride lipase (HTGL) accumulate IDL in the plasma.

LDL particles account for approximately 70% of the plasma cholesterol in normal individuals. LDL receptors are present on the surfaces of nearly all cells. Most LDL is taken up by the liver, and the rest is transported to peripheral tissues such as the adrenal glands and gonads for steroid synthesis. Dyslipidemia is greatly influenced by LDL-R activity. The efficiency with which VLDL is converted into LDL is also important in lipid homeostasis.

Hyperlipoproteinemias

Hypercholesterolemia (Table 80-8)

Homozygous FH

FH homozygotes inherit 2 abnormal LDL receptor genes, resulting in markedly elevated plasma cholesterol levels ranging between 500 and 1,200 mg/dL. Triglyceride levels are normal to mildly elevated, and HDL levels may be slightly decreased. The condition occurs in 1/1,000,000 persons. Receptor negative patients have <2% normal LDL receptor activity, whereas those who are receptor defective may have as much 25% normal activity and a better prognosis.

The prognosis is poor regardless of the specific LDL receptor aberration. Severe atherosclerosis involving the aortic root and coronary arteries is present by early- to mid-childhood. These children usually present with xanthomas, which may cause thickening of the Achilles tendon or extensor tendons of the hands, or cutaneous lesions on the hands, elbows, knees, or buttocks (Figs. 80-10, 80-11, and 80-12). Corneal arcus may be present. Family history is informative because premature heart disease is strongly prevalent among relatives of both parents. The diagnosis may be confirmed by measuring LDL receptor activity in cultured skin fibroblasts. Phenotypic expression of the disease may also be assessed by measuring receptor activity on the surface of lymphocytes by using cell sorting techniques.

image

Figure 80-10 Achilles tendon xanthoma (heterozygous familial hypercholesterolemia).

(From Durrington P: Dyslipidaemia, Lancet 362:717–731, 2003.)

image

Figure 80-11 Striate palmar xanthomata.

(From Durrington P: Dyslipidaemia, Lancet 362:717–731, 2003.)

image

Figure 80-12 Eruptive xanthomata on extensor surface of forearm.

(From Durrington P: Dyslipidaemia, Lancet 362:717–731, 2003.)

Untreated homozygous patients rarely survive to adulthood. Symptoms of coronary insufficiency may occur; sudden death is common. LDL apheresis to selectively remove LDL particles from the circulation is recommended for many children and has been shown to slow the progression of atherosclerosis. Liver transplantation has also been successful in decreasing LDL cholesterol levels, but complications related to immunosuppression are common. HMG CoA reductase inhibitors are often effective depending on the specific class of LDL receptor defect present. Combination therapy with ezetimibe, selectively blocking cholesterol adsorption in the gut, usually results in further modest decline in LDL levels; it has largely replaced the use of bile acid sequestrants.

Heterozygous FH

Heterozygous FH is one of the most common single gene mutations associated with acute coronary syndromes and atherosclerotic CHD in adults. Its prevalence is approximately 1/500 individuals worldwide, but the frequency may be as high as 1/250 in selected populations such as French-Canadians, Afrikaners, and Christian Lebanese due to the founder effect of unique new mutations.

Heart disease accounts for more than half of all deaths in Western society. The pathogenesis of CHD is both environmental and genetic, and the complex interrelationship between the two determines the phenotypic expression of disease. Chinese people with heterozygous FH living in China have a mean LDL cholesterol of 168 mg/dL, whereas immigrant Chinese with the disease living in Canada average 288 mg/dL. This dramatic disparity in lipoprotein levels between geographic locations is expected to narrow as dietary and physical activity practices in China approximate those of the industrialized West.

Because heterozygous FH is a co-dominant condition with nearly full penetrance 50% of first-degree relatives of affected individuals will have the disease, as will 25% of second-degree relatives. An estimated 10 million people have FH worldwide. Symptoms of CHD usually occur at the mean age of 45-48 yr in males, and a decade later in females.

The World Health Organization (WHO) has targeted FH for individualized intervention strategies because of its large effect on morbidity and mortality. A relatively small percentage of the population accounts for a disproportionately high share of the burden of CVD. The clinical expression of the disease is straightforward and treatment is effective.

One cannot overemphasize the importance of family history for suspecting the possibility of FH. Indeed, the whole basis for deciding which children should have blood cholesterol testing is determined by a family history of premature CHD and/or parental hypercholesterolemia.

Plasma levels of LDL cholesterol do not allow unequivocal diagnosis of FH heterozygotes, but values are generally twice normal for age because of one absent or dysfunctional allele. The U.S. MED-PED (“make early diagnosis-prevent early death”) Program based in Utah has formulated diagnostic criteria. Similar criteria with minor variation exist in the United Kingdom and Holland. The diagnosis within well-defined FH families is predictable according to LDL cut points. More stringent criteria are required to establish the diagnosis in previously undiagnosed families, requiring strong evidence of an autosomal inheritance pattern and higher LDL cut points. At a total cholesterol level of 310 mg/dL, only 4% of persons in the general population would have FH, whereas 95% of persons who were first-degree relatives of known cases would have the disease. The mathematical probability of FH, verified by molecular genetics, is derived from a U.S. population cohort and may not be applicable to other countries.

Very high cholesterol levels in children should prompt extensive screening of adult first- and second-degree relatives (“reverse” cholesterol screening). A child younger than 18 yr with total plasma cholesterol of 270 mg/dL and/or LDL-C of 200 mg/dL has an 88% chance of having FH. If there is a first-degree relative with proven FH, the diagnosis in the child is virtually certain (Table 80-9). Conversely, criteria for diagnosing probable FH in a child whose first-degree relative has known FH require only modest elevation of total cholesterol to 220 mg/dL (LDL-C 155 mg/dL).

Treatment of children with FH should begin with a rather rigorous low-fat diet (see later). Diet alone is rarely sufficient for decreasing blood cholesterol levels to acceptable levels (LDL-C <130 mg/dL). The Expert Panel on Blood Cholesterol Levels in Children and Adolescents (National Cholesterol Education Program) has promulgated guidelines for the consideration of cholesterol lowering medication in children at least 10 yr of age. Such consideration should be given if the LDL-C is >160 mg/dL in the presence of a strong history of premature heart disease in the family; or >190 mg/dL even in the absence of a positive family history, for example, if the child is adopted and family history is not available.

Ezetimibe blocks cholesterol adsorption in the gastrointestinal tract and has a low risk of side effects. Preliminary data suggest that ezetimibe will lower total cholesterol by 20-30 mg/dL. This medication has not been evaluated by controlled clinical trials in children. HMG CoA reductase inhibitors have become the drug of choice for treatment of FH because of their remarkable effectiveness and acceptable risk profile. There is sufficient clinical experience with this class of drugs in children to document that they are as effective in children as adults, and the risks of elevated hepatic enzymes and myositis are no greater than in adults.

Hypercholesterolemia with Hypertriglyceridemia

Familial Combined Hyperlipidemia (FCHL)

This is an autosomal dominant condition characterized by moderate elevation in plasma LDL cholesterol and triglycerides, and reduced plasma HDL cholesterol. It is the most common primary lipid disorder, occurring in approximately 1/200 people. No single metabolic aberration has been identified linking FCHL with atherogenesis, but it is well documented that about 20% of individuals who develop CHD by 60 yr of age have FCHL. Family history of premature heart disease is typically positive; the formal diagnosis requires that at least two first-degree relatives have evidence of one of three variants of dyslipidemia: (1) >90th percentile plasma LDL cholesterol; (2) >90th percentile LDL cholesterol and triglycerides; and (3) >90th percentile triglycerides. Individuals switch from one phenotype to another. Xanthomas are not a feature of FCHL. Elevated plasma apoB levels with increased small dense LDL particles support the diagnosis.

Children and adults with FCHL have co-existing adiposity, hypertension, and hyperinsulinemia, suggesting the presence of the metabolic syndrome. Formal diagnosis of this multiplex syndrome as defined by the NCEP’s Adult Treatment Panel III (ATP III) identifies 6 major components: abdominal obesity, atherogenic dyslipidemia, hypertension, insulin resistance with or without impaired glucose tolerance, evidence of vascular inflammation, and prothrombotic state. It is estimated that 30% of overweight adults fulfill criteria for the diagnosis of metabolic syndrome, including 65% of those with FCHL. Hispanics and South Asians from the Indian subcontinent are especially susceptible.

The mechanisms associating visceral adiposity with the metabolic syndrome and type II diabetes are not fully understood. A plausible unifying principal is that obesity causes endoplasmic reticulum stress, leading to suppression of insulin receptor signaling and thus insulin resistance and heightened inflammatory response. How this relates to atherogenesis is unclear. It is assumed that hypercholesterolemia and, with less certainty, hypertriglyceridemia confer risk for CVD in patients with FCHL. When features of the metabolic syndrome are included in logistic models shared etiologic features such as increased visceral adiposity become apparent. Visceral adiposity increases with age and its importance in children as a risk factor for heart disease and diabetes is limited by the relative paucity of data. Though longitudinal measurement of waist circumference and the presence of intra-abdominal fat as determined by MRI is being conducted in the research setting, body mass index (BMI) remains the surrogate for adiposity in the pediatric clinical setting.

The metabolic syndrome is a dramatic illustration of the interaction of genetics and the environment. Genetic susceptibility is essential as an explanation for premature heart disease in individuals with FCHL. Unhealthy lifestyle, poor diet, and physical inactivity contribute to obesity and attendant features of the metabolic syndrome.

The cornerstone of management is lifestyle modification. This includes a diet low in saturated fats, trans fats, and cholesterol, as well as reduced consumption of simple sugars. Increased dietary intake of fruits and vegetables is important, as is 1 hr of moderate physical activity daily. Compliance among children and their parents is often a problem, but small incremental steps are more likely to succeed than aggressive weight-loss strategies. It is very important that the child’s caregivers participate in the process. Plasma triglyceride levels are usually quite responsive to dietary restriction, especially reduction in the amount of sweetened drinks consumed. Blood cholesterol levels may decrease by 10-15%, but if LDL cholesterol remains >160 mg/dL, drug therapy should be considered.

Familial Dysbetalipoproteinemia (Fdbl, Type III Hyperlipoproteinemia)

FDBL is caused by mutations in the gene for apolipoprotein E (apoE), which when exposed to environmental influences such as high fat, high caloric diet, or excessive alcohol intake, results in a mixed type of hyperlipidemia. Patients tend to have elevated plasma cholesterol and triglycerides to a relatively similar degree. HDL cholesterol is typically normal in contrast to other causes of hypertriglyceridemia associated with low HDL. This rare disorder affects about 1/10,000 persons. ApoE mediates removal of chylomicron and VLDL remnants from the circulation by binding to hepatic surface receptors. The polymorphic apoE gene expresses in three isoforms: apoE3, apoE2, and apoE4. E4 is the “normal” allele present in the majority of the population. The apoE2 isoform has lower affinity for the LDL receptor and its frequency is about 7%. About 1% of the population is homozygous for apoE2/E2, the most common mutation associated with FDBL, but only a minority express the disease. Expression requires precipitating illnesses such as diabetes, obesity, renal disease, or hypothyroidism. Individuals homozygous for apoE4/E4 are at risk for late-onset Alzheimer disease.

Most patients with FDBL present in adulthood with distinctive xanthomas. Tuberoeruptive xanthomas resemble small grapelike clusters on the knees, buttocks, and elbows. Prominent orange-yellow discoloration of the creases of the hands (palmar xanthomas) is also typically present. Atherosclerosis, often presenting with peripheral vascular disease, usually occurs in the 4th or 5th decade. Children may present with a less distinctive rash and generally have precipitating illnesses.

The diagnosis of FDBL is established by lipoprotein electrophoresis, which demonstrates a broad beta band containing remnant lipoproteins. Direct measurement of VLDL by ultracentrifugation can be performed in specialized lipid laboratories. A VLDL/total triglyceride ratio >0.30 supports the diagnosis. ApoE genotyping for apoE2 homozygosity can be performed, confirming the diagnosis in the presence of the distinctive physical findings. A negative result does not necessarily rule out the disease as other mutations in apoE may cause even more serious manifestations.

Pharmacologic treatment of FDBL is necessary to decrease the likelihood of symptomatic atherosclerosis in adults. HMG CoA reductase inhibitors, nicotinic acid, and fibrates are all effective. FDBL is quite responsive to recommended dietary restriction.

Hypertriglyceridemias

The familial disorders of triglyceride-rich lipoproteins include both common and rare variants of the Frederickson classification system. These include chylomicronemia (type I), familial hypertriglyceridemia (type IV), and the more severe combined hypertriglyceridemia and chylomicronemia (type V). Hepatic lipase (HL) deficiency also results in a similar combined hyperlipidemia.

Familial Chylomicronemia (Type I Hyperlipidemia)

This rare single gene defect, like familial hypercholesterolemia, is due to mutations affecting clearance of apoB-containing lipoproteins. Deficiency or absence of lipoprotein lipase (LPL) or its cofactor apoC-II, which facilitates lipolysis by LPL, causes severe elevation of triglyceride rich plasma chylomicrons. HDL cholesterol levels are decreased. As clearance of these particles is markedly delayed, the plasma is noted to have a turbid appearance even after prolonged fasting (Fig. 80-13). Chylomicronemia caused by LPL deficiency is associated with modest elevation in triglycerides, whereas this is not the case when the cause is deficient or absent apoC-II. Both are autosomal recessive conditions with a frequency of approximately 1/1,000,000. The disease usually presents during childhood with acute pancreatitis. Eruptive xanthomas on the arms, knees, and buttocks may be present, and there may be hepatosplenomegaly. The diagnosis is established by assaying triglyceride lipolytic activity. Treatment of chylomicronemia is by vigorous dietary fat restriction supplemented by fat-soluble vitamins. Medium-chain triglycerides that are adsorbed into the portal venous system may augment total fat intake, and administration of fish oils may also be beneficial.

image

Figure 80-13 Milky plasma from patient with acute abdominal pain.

(From Durrington P: Dyslipidaemia, Lancet 362:717–731, 2003.)

Familial Hypertriglyceridemia (FHTG, Type IV Hyperlipidemia)

FHTG is an autosomal dominant disorder of unknown etiology, which occurs in about 1/500 individuals. It is characterized by elevation of plasma triglycerides >90th percentile (250-1,000 mg/dL range), often accompanied by slight elevation in plasma cholesterol and low HDL. FHTG does not usually manifest until adulthood, though it is expressed in about 20% of affected children. In contrast to FCHL, FHTG is not thought to be highly atherogenic. It is most likely caused by defective breakdown of VLDL, or less often by overproduction of this class of lipoproteins.

The diagnosis should include the presence of at least one first-degree relative with hypertriglyceridemia. FHTG should be distinguished from FCHL and FDBL, as the latter require more vigorous treatment to prevent coronary or peripheral vascular disease. The differentiation is usually possible on clinical grounds, in that lower LDL cholesterol levels accompany FHTG, but measurement of normal apoB levels in FHTG may be helpful in ambiguous situations.

A more severe hypertriglyceridemia characterized by increased levels of chylomicrons as well as VLDL particles (Frederickson type V) may occasionally be encountered. Triglyceride levels are often >1,000 mg/dL. The disease is rarely seen in children. In contrast to chylomicronemia (Frederickson type I), LPL or apoC-II deficiency is not present. These patients often develop eruptive xanthomas in adulthood, whereas type IV hypertriglyceridemia individuals do not. Acute pancreatitis may be the presenting illness. As with other hypertriglyceridemias, excessive alcohol consumption and estrogen therapy can exacerbate the disease.

Secondary causes of transient hypertriglyceridemia should be ruled out before making a diagnosis of FHTG. A diet high in simple sugars and carbohydrates, or excessive alcohol consumption as well as estrogen therapy may exacerbate hypertriglyceridemia. Adolescents and adults should be questioned about excessive consumption of soda and other sweetened drinks, as it is common to encounter people who drink supersized drinks or multiple 12 oz cans of sweetened drinks daily. Cessation of this practice often results in dramatic fall in triglyceride levels as well as weight among those who are obese. HDL cholesterol levels will tend to rise as BMI stabilizes.

Pediatric diseases associated with hyperlipidemia include hypothyroidism, nephrotic syndrome, biliary atresia, glycogen storage disease, Niemann-Pick disease, Tay-Sachs disease, systemic lupus erythematosus, hepatitis, and anorexia nervosa (Table 80-10). Certain medications exacerbate hyperlipidemia, including isotretinoin (Accutane), thiazide diuretics, oral contraceptives, steroids, β-blockers, immunosuppressants, and protease inhibitors used in the treatment of HIV.

Table 80-10 SECONDARY CAUSES OF HYPERLIPIDEMIA

HYPERCHOLESTEROLEMIA

Hypothyrodism

Nephrotic syndrome

Cholestasis

Anorexia nervosa

Drugs: progesterone, thiazides, tegretol, cyclosporine

HYPERTRIGLYCERIDEMIA

Obesity

Type II diabetes

Alcohol

Renal failure

Sepsis

Stress

Cushing syndrome

Pregnancy

Hepatitis

AIDS, protease inhibitions

Drugs: anabolic steroids, β blockers, estrogen, thiazides

REDUCED HIGH-DENSITY LIPOPROTEIN

Smoking

Obesity

Type II diabetes

Malnutrition

Drugs: β Blockers, anabolic steroids

Treatment of hypertriglyceridemia in children rarely requires medication unless levels >1,000 mg/dL persist after dietary restriction of fats, sugars, and carbohydrates, accompanied by increased physical activity. In such cases, the aim is to prevent episodes of pancreatitis. The common use of fibrates (fenofibric acid) and niacin in adults with hypertriglyceridemia is not recommended in children. HMG CoA reductase inhibitors are reasonably effective in lowering triglyceride levels, and there is considerably more experience documenting the safety and efficacy of this class of lipid lowering medications in children.

Disorders of HDL Metabolism

Conditions Associated with Low Cholesterol

Disorders of apoB-containing lipoproteins and intracellular cholesterol metabolism are associated with low plasma cholesterol.

Abetalipoproteinemia

This rare autosomal recessive disease is caused by mutations in the gene encoding microsomal triglyceride transfer protein necessary for the transfer of lipids to nascent chylomicrons in the small intestine and VLDL in the liver. This results in absence of chylomicrons, VLDL, LDL, and apoB, and very low levels of plasma cholesterol and triglycerides. Fat malabsorption, diarrhea, and failure to thrive present in early childhood. Spinocerebellar degeneration, secondary to vitamin E deficiency, manifests in loss of deep tendon reflexes progressing to ataxia and lower extremity spasticity by adulthood. Patients with abetalipoproteinemia also acquire a progressive pigmented retinopathy associated with decreased night and color vision and eventual blindness. The neurologic symptoms and retinopathy may be mistaken for Friedreich ataxia. Differentiation from Friedreich ataxia is suggested by the presence of malabsorption and acanthocytosis on peripheral blood smear in abetalipoproteinemia. Many of the clinical manifestations of the disease are a result of malabsorption of fat-soluble vitamins, such as vitamins E, A, and K. Early treatment with supplemental vitamins, especially E, may significantly slow the development of neurologic sequelae. Vitamin E is normally transported from the small intestine to the liver by chylomicrons, where it is dependent on the endogenous VLDL pathway for delivery into the circulation and peripheral tissues. Parents of children with abetalipoproteinemia have normal blood lipid and apoB levels.

Smith-Lemli-Opitz Syndrome (SLOS)

Patients with SLOS often have multiple congenital anomalies and developmental delay caused by low plasma cholesterol and accumulated precursors (Tables 80-11 and 80-12). Family pedigree analysis has revealed its autosomal recessive inheritance pattern. Mutations in the DHCR7 (7-dehydrocholesterol-Δ7 reductase) gene result in deficiency of the microsomal enzyme DHCR7, which is necessary to complete the final step in cholesterol synthesis. It is not known why defects in cholesterol synthesis result in congenital malformations, but as cholesterol is a major component of myelin and a contributor to signal transduction in the developing nervous system, neurodevelopment is severely impaired. The incidence of SLOS is estimated to be 1/20,000-60,000 births among whites, with a somewhat higher frequency in Hispanics and lower incidence in individuals of African descent.

Table 80-11 MAJOR CLINICAL CHARACTERISTICS OF SMITH-LEMLI-OPITZ SYNDROME: FREQUENT ANOMALIES (>50% OF PATIENTS)

CRANIOFACIAL

Microcephaly

Blepharoptosis

Anteverted nares

Retromicrognathia

Low-set, posteriorly rotated ears

Midline cleft palate

Broad maxillary alveolar ridges

Cataracts (<50%)

SKELETAL ANOMALIES

Syndactyly of toes II/III

Postaxial polydactyly (<50%)

Equinovarus deformity (<50%)

GENITAL ANOMALIES

Hypospadias

Cryptorchidism

Sexual ambiguity (<50%)

DEVELOPMENT

Pre- and postnatal growth retardation

Feeding problems

Mental retardation

Behavioral abnormalities

From Haas D, Kelley RI, Hoffmann GF: Inherited disorders of cholesterol biosynthesis, Neuropediatrics 32:113–122, 2001.

Table 80-12 CHARACTERISTIC MALFORMATIONS OF INTERNAL ORGANS IN SEVERELY AFFECTED SMITH-LEMLI-OPITZ PATIENTS

CENTRAL NERVOUS SYSTEM

Frontal lobe hypoplasia

Enlarged ventricles

Agenesis of corpus callosum

Cerebellar hypoplasia

Holoprosencephaly

CARDIOVASCULAR

Atrioventricular canal

Secundum atrial septal defect

Patent ductus arteriosus

Membranous ventricular septal defect

URINARY TRACT

Renal hypoplasia or aplasia

Renal cortical cysts

Hydronephrosis

Ureteral duplication

GASTROINTESTINAL

Hirschsprung disease

Pyloric stenosis

Refractory dysmotility

Cholestatic and noncholestatic progressive liver disease

PULMONARY

Pulmonary hypoplasia

Abnormal lobation

ENDOCRINE

Adrenal insufficiency

From Haas D, Kelley RI, Hoffmann GF: Inherited disorders of cholesterol biosynthesis, Neuropediatrics 32:113–122, 2001.

Spontaneous abortion of SLOS fetuses may occur. Type II SLOS often leads to death by the end of the neonatal period. Survival is unlikely when the plasma cholesterol level is <20 mg/dL. Laboratory measurement should be performed by gas chromatography, as standard techniques for lipoprotein assay include measurement of cholesterol precursors, which may yield a false positive result. Milder cases may not present until late childhood. Phenotypic variance ranges from microcephaly, cardiac and brain malformation, and multiple organ-system failure to only subtle dysmorphic features and mild developmental delay. Treatment includes supplemental dietary cholesterol (egg yolk) and HMG CoA reductase inhibition to prevent the synthesis of toxic precursors proximal to the enzymatic block.

Lipoprotein Patterns in Children and Adolescents

Table 80-13, derived primarily from the Lipid Research Clinics Population Studies, shows the distribution of lipoprotein levels in American youth at various ages. Total plasma cholesterol rises rapidly from a mean of 68 mg/dL at birth to a level approximately twice that by the end of the neonatal period. A very gradual rise in total cholesterol level occurs until puberty, at which time the mean level reaches 160 mg/dL. Total cholesterol falls transiently during puberty, in males due to a small decrease in HDL cholesterol, and in females secondary to a slight fall in LDL cholesterol. Blood cholesterol levels track reasonably well as individuals age. High blood cholesterol tends to aggregate in families, a reflection of genetic and environmental influences.

Acceptable total cholesterol among children and adolescents is <170 mg/dL; borderline is 170-199 mg/dL; and high >200 mg/dL. Acceptable LDL cholesterol is <110 mg/dL; borderline 110-129 mg/dL; and high >130 mg/dL. HDL cholesterol should be >40 mg/dL.

Blood Cholesterol Screening

Guidelines for cholesterol measurement in children were updated by the American Academy of Pediatricians in 2008. A targeted approach to cholesterol screening for children remains in effect:

Whereas Lipid Research Clinics data referenced in the original NCEP guidelines predicted that selective blood cholesterol screening of children would apply to a quarter of American youth, more recent population-based studies such as the National Health and Nutrition Examination Surveys (NHANES), predict that nearly half of children fulfill criteria for screening. The increase is likely due to the worrisome rise in youth obesity.

Being overweight confers special risk of CVD because of the strong association with the insulin resistance syndrome (metabolic syndrome). Though there is no single definition of metabolic syndrome defined for youth, it is likely that half of all severely obese children are insulin resistant. Among a large cohort of 5th grade school children who had comprehensive screening of CVD risk factors conducted by the Coronary Artery Risk Detection in Appalachian Communities (CARDIAC) Project, 49% of those with the hyperpigmented rash, acanthosis nigricans, had 3 or more risk factors for the metabolic syndrome, including insulin resistance, hypertension, and abnormal lipid levels (triglycerides >150 mg/dL; HDL-C <40 mg/dL) (Chapter 44).

Reliance on family history of premature heart disease, or known parental hypercholesterolemia greater than 240 mg/dL, is considered by some to be too insensitive and difficult to apply. Indeed, over half of children with hypercholesterolemia will be missed by the targeted approach to screening. It was predicted that those with severe genetic predisposition to premature heart disease, such as familial hypercholesterolemia (FH), would be identified by application of selective criteria for screening. However, data from the CARDIAC Project found that universal screening of youth identified just as many children with severe dyslipidemia who did not fulfill criteria as those who did.

It is possible that, in the future, guidelines regarding blood cholesterol screening in childhood may be liberalized further to include all children because of newer information and changing circumstances. It is well documented that many parents are unaware of their own cholesterol levels, making the criteria problematic. The evidence that cholesterol screening of children may cause psychological harm to the child is less than compelling, as is the concern that universal screening might lead to overuse of cholesterol lowering medication by practitioners. Finally, the epidemic of childhood obesity, approaching 50% in some disadvantaged high-risk populations, supports broader screening to identify those with the metabolic syndrome. A fasting lipid profile is recommended in order to detect hypertriglyceridemia and/or low HDL cholesterol often found in this pre-diabetic condition. The AAP guidelines recommend that blood cholesterol testing occur sometime after age 2 yr but no later than age 10 yr.

Risk Assessment and Treatment of Hyperlipidemia

The National Cholesterol Education Program (NCEP) recommends a population-based approach toward healthy lifestyle applicable to all children, and an individualized approach directed at those children at high risk (Fig. 80-14). The important focus on maintenance of a healthy lifestyle rather than aggressive weight reduction is recommended by the AAP.

The AHA Step I diet, with updated dietary recommendations based on new U.S. Department of Agriculture guidelines, is still applicable to most children older than 2 yr:

Persistence of an elevated LDL cholesterol >130 mg/dL indicates the need for more comprehensive evaluation and lifestyle modification. History and physical examination and additional laboratory tests aimed at ruling out secondary causes of hyperlipidemia (see Table 80-10) should be performed. Other family members should have blood cholesterol screening. If the LDL cholesterol level does not achieve the minimal goal of <130 mg/dl the AHA Step II diet should be recommended. This diet allows the same average fat consumption of no more than 30% of total calories, but restricts saturated fats to <7-8% of total calories and cholesterol intake to <200 mg per day. Follow-up lab tests, measurement of height and weight for the calculation of body mass index (BMI), and dietary history should be scheduled at 3-6 mo intervals.

The 2004 revision of the NCEP Adult Treatment Panel III raised the minimal acceptable level of HDL cholesterol from 35 mg/dL to 40 mg/dL. If low HDL cholesterol is present, counseling directed toward weight management, tobacco avoidance, and daily physical activity should be provided.

No restriction of fat or cholesterol is recommended for infants less than 2 yr of age because of rapid growth and development, especially involving the central nervous system. Overfeeding should be discouraged as increasingly infants and toddlers are exceeding weight for height standards published by the U.S. Centers for Disease Control and Prevention. The myth that “a bigger baby is a healthier baby” persists.

The safety of a heart healthy diet among children 3-19 yr has been established by the National Health and Nutrition Examination Survey (NHANES III). Despite a decrease in the average level of fat intake from the second survey there was no evidence of poor growth or compromised nutritional status. The prospective, well-controlled Dietary Intervention Study in Children (DISC) compared children consuming a low-fat Step I diet with subjects consuming the “usual” diet containing 33-34% of calories as fat, and 13% as saturated fat. No differences between groups with regard to height, weight, micronutrients, or psychological well-being were observed. Children on the low-fat diet had lower LDL cholesterol levels.

The Committee on Nutrition of the American Academy of Pediatrics suggests that as children older than 2 yr consume fewer calories from fat, they should eat more grain product, fruits, vegetables, low-fat milk products, beans, lean meats, poultry, fish, and other protein-rich foods. Low-carbohydrate, high-fat diets have become popular over the last decade as a means to achieve weight reduction. Unlimited fat intake is strongly discouraged, as is unrestricted sugar and carbohydrate consumption. Carbohydrates should comprise about 55% of calories, achieved by consuming complex carbohydrates such as pasta, some vegetables, potatoes, legumes, and whole grain cereals and bread.

Protein should provide about 15-20% of calories, and should contain all of the essential fatty acids. The exclusion of meat or fish from the diet necessitates a healthy mixture of plant proteins in order to achieve appropriate nutrient balance. Thus foods high in fiber, such as fruits, vegetables, and whole grains are recommended because of their excellent nutrient content as components of a low saturated fat eating pattern. Children should eat 5 or more fruits and vegetables daily. Canned and frozen vegetables and soups should be selected for low sodium content.

If followed, these dietary recommendations provide adequate calories for optimal growth and development without promoting obesity. Compliance on the part of children and their caregivers is challenging in today’s society. Children learn eating habits from their parents. Successful adoption of a healthier diet is far more likely to occur if meals and snacks in the home are applicable to the entire family rather than an individual child. A regular time for meals together as a family is desirable. Grandparents and other nonparental caregivers sometimes need to be reminded not to indulge the child who is on a restricted diet. The rise in obesity is prompting some school districts to restrict sweetened drink availability, and offer more nutritious cafeteria selections.

The rise in sedentary activity among our youth is contributing to the increase in obesity nationwide, in turn increasing the prevalence of other risk factors such as dyslipidemia and hypertension. The National Association for Sport and Physical Education (NASPE) recommends that children should accumulate at least 60 min of age-appropriate physical activity on most days of the week. Extended periods (2 hr or more) of daytime inactivity are discouraged, as is more than 2 hr of television and other forms of screen time.

Drug Therapy (Tables 80-14 And 80-15)

The AAP has slightly modified the original 1992 NCEP guidelines in that consideration be given to pharmacologic treatment of hyperlipidemia if the child is at least 8 yr of age and an adequate period of dietary restriction has not achieved therapeutic goals. Drug therapy should be considered when:

Table 80-15 SIDE EFFECTS OF LIPID-LOWERING DRUGS

DRUG AND SITE OR TYPE OF EFFECT EFFECT
STATINS
Skin Rash
Nervous system Loss of concentration, sleep disturbance, headache, peripheral neuropathy
Liver Hepatitis, loss of appetite, weight loss, and increases in serum aminotransferases to two to three times the upper limit of the normal range
Gastrointestinal tract Abdominal pain, nausea, diarrhea
Muscles Muscle pain or weakness, myositis (usually with serum creatine kinase >1,000U/L), rhabdomyolysis with renal failure
Immune system Lupus-like syndrome (lovastatin, simvastatin, or fluvastatin)
Protein binding Diminished binding of warfarin (lovastatin, simvastatin, fluvastatin)
BILE ACID-BINDING RESINS
Gastrointestinal tract Abdominal fullness, nausea, gas, constipation, hemorrhoids, anal fissure, activation of diverticulitis, diminished absorption of vitamin D in children
Liver Mild serum aminotransferase elevations, which can be exacerbated by concomitant treatment with a statin
Metabolic system Increases in serum triglycerides of ≈10% (greater increases in patients with hypertriglyceridemia)
Electrolytes Hyperchloremic acidosis in children and patients with renal failure (cholestyramine)
Drug interactions Binding of warfarin, digoxin, thiazide diuretics, thyroxine, statins
NICOTINIC ACID
Skin Flushing, dry skin, pruritus, ichthyosis, acanthosis nigricans
Eyes Conjunctivitis, cystoid macular edema, retinal detachment
Respiratory tract Nasal stuffiness
Heart Supraventricular arrhythmias
Gastrointestinal tract Heartburn, loose bowel movements or diarrhea
Liver Mild increase in serum aminotransferases, hepatitis with nausea and fatigue
Muscles Myositis
Metabolic system Hyperglycemia (incidence, ≈5% higher in patients with diabetes), increase of 10% in serum uric acid
FIBRATES
Skin Rash
Gastrointestinal tract Stomach upset, abdominal pain (mainly gemfibrozil), cholesterol-saturated bile, increase of 1-2% in gallstone incidence
Genitourinary tract Erectile dysfunction (mainly clofibrate)
Muscles Myositis with impaired renal function
Plasma proteins Interference with binding of warfarin, requiring reduction in the dose of warfarin by ≈30%
Liver Increased serum aminotransferases

From Knopp RH: Drug treatment of lipid disorders, N Engl J Med 341:498–512, 1999.

These arbitrary but sensible guidelines are based on the statistical probability of the child having an inherited form of dyslipidemia such as heterozygous familial hypercholesterolemia (FH). Pharmacologic treatment of children less than 8 yr of age should be reserved for the rare child with homozygous FH and LDL cholesterol levels exceeding 500 mg/dL.

Considerable experience with drug therapy in children and adolescents with hyperlipidemia over the past 15 yr has expanded therapeutic options, improved compliance, and enhanced efficacy. In the past, the mainstay of drug therapy was bile acid sequestrants such as cholestyramine and colestipol because they were not systemically absorbed. Interruption of the enterohepatic circulation of bile acids promotes synthesis in the liver of new bile acids from cholesterol. Gastrointestinal side effects and taste resulted in less than desirable compliance, even when there were few viable options.

HMG-CoA reductase inhibitors, known also as “statins” are remarkably effective in lowering LDL cholesterol levels and reducing plaque inflammation, thereby reducing the likelihood of a sudden coronary event in an at-risk adult within weeks of starting the medication. As a class they work by blocking the intrahepatic biosynthesis of cholesterol, thereby stimulating the production of more LDL receptors on the cell surface. The NCEP Adult Treatment Panel now advocates aggressive lowering of LDL to below 70 mg/dL in individuals with known coronary heart disease. This information is relevant because children who fulfill criteria for consideration of cholesterol lowering medication will almost always have inherited the condition from one of his or her parents. Not infrequently when providing care for the child questions come up about screening and treatment of parents or grandparents. Statins are equally effective in children, capable of lowering LDL cholesterol levels by half when necessary. They also will effect modest reduction in triglycerides and inconsistent increase in HDL cholesterol. Their side-effect profile, mainly liver dysfunction and rarely rhabdomyolysis with secondary renal failure, should be taken into consideration before prescribing the drug. However, there has been no evidence to date that complications are any more frequent in children than adults, and skeletal muscle discomfort seems to be somewhat less of a problem. Statins are contraindicated in patients with active liver disease and during pregnancy and lactation. Children should have liver enzymes monitored regularly, and creatine phosphokinase (CPK) measured if muscle aches or weakness occurs. Liver enzymes may be allowed to rise threefold before discontinuing the drug. It should be reemphasized that children with modest elevations in cholesterol, such as that seen in polygenic hypercholesterolemia, are not candidates for statins as a rule because of their side-effect profile.

Other cholesterol lowering medications such as nicotinic acid and fibrates have been used far less often in children than bile acid sequestrants and statins. Nicotinic acid has been used selectively in children with marked hypertriglyceridemia at risk for acute pancreatitis, though dietary restriction of complex sugars and carbohydrates will usually result in significant lowering of triglyceride levels.

Ezetimibe has proven to be especially useful in the pediatric population because of its efficacy and low side-effect profile. Ezetimibe reduces plasma LDL cholesterol by blocking sterol absorption in enterocytes. The drug is marketed as an adjunct to statins when adult subjects are not achieving sufficient blood lipid lowering with statins alone. Not surprisingly, large clinical trials of ezetimibe used as monotherapy in children have not been conducted because the potential market in the pediatric age group is small. Nevertheless there are sufficient reports in the literature documenting the impressive effectiveness of this medication without worrisome side-effects that one can feel on relatively safe grounds recommending it instead of a statin when moderate hypercholesterolemia is encountered. The dose is 10 mg taken once daily. Parents concerned about the possibility of lifelong use of statins as a treatment are generally much more receptive to the use of ezetimibe. Regardless of which drug is selected for a given child or adolescent in need of pharmacologic treatment, the goal is to decrease the LDL cholesterol to <130 mg/dL, or more ideally <110 mg/dL. There is no reason to push LDL levels lower as is recommended in high-risk adults.

Bibliography

Austin MA, Hutter CH, Zimmern RL, et al. Familial hypercholesterolemia and coronary heart disease: a huge association review. Am J Epidemiol. 2004;160:421-429.

Bhatnagar D, Soran H, Durrington PN. Hypercholesterolaemia and its management. BMJ. 2008;337:503-508.

Brunzell JD. Hypertriglyceridemia. N Engl J Med. 2007;357:1009-1016.

Centers for Disease Control and Prevention. Prevalence of abnormal lipid levels among youths—United States, 1999–2006. MMWR. 2010;59:29-33.

Chan YM, Merkens LS, Connor WB, et al. Effects of dietary cholesterol and simvastatin on cholesterol synthesis in Smith-Lemli-Opitz syndrome. Pediatr Res. 2009;65:681-685.

Daniels SR, Greer FR, et al. Lipid screening and cardiovascular health in childhood. Pediatrics. 2008;122:198-208.

De Jongh S, Ose L, Szamosi T, et al. Efficacy and safety of statin therapy in children with familial hypercholesterolemia. Circulation. 2002;106:2231-2237.

Ford ES, Li C, Zhao G, Mokdad AH. Concentrations of low-density lipoprotein cholesterol and total cholesterol among children and adolescents in the United States. Circulation. 2009;119:1108-1115.

Grundy SM, Hansen B, Smith SC, et al. Clinical management of metabolic syndrome: report of the American Heart Association/National Heart, Lung, Blood Institute/American Diabetes Association Conference on Scientific Issues Related to Management. Circulation. 2004;109:551-556.

Kumanyika SK, Obarzanek E. Population-based prevention of obesity. The need for comprehensive practices of healthful eating, physical activity and energy balance. A scientific statement from American Heart Association Council on Epidemiology and Prevention. Circulation. 2008;118:428-464.

Lebenthal Y, Horvath A, Dziechciarz P, et al. Are treatment targets for hypercholesterolemia evidence-based? Systematic review and meta-analysis of randomized controlled trials. Arch Dis Child. 2010;95:673-680.

Magnussen CG, Raitakari OT, Thomson R, et al. Utility of currently recommended pediatric dyslipidemia classifications in predicting dyslipidemia in adulthood. Circulation. 2008;117:32-42.

Manlhiot C, Larsson P, Gurofsky R, et al. Spectrum and management of hypertriglyceridemia among children in clinical practice. Pediatrics. 2009;123:458-465.

The Medical Letter. Fenofibric acid (trilipix). Med Lett. 2009;51:33-34.

Merkens LS, Connor WE, Linck LM, et al. Effects of dietary cholesterol on plasma lipoproteins in Smith-Lemli-Opitz syndrome. Pediatr Res. 2004;56:726-732.

Raitakari OT. Arterial abnormalities in children with familial hypercholesteremia. Lancet. 2004;363:342-343.

The SEARCH Collaborative Group. SLCO1B1 variants and statin-induced myopathy—a genomewide study. N Engl J Med. 2008;359:789-799.

Silverstein J, Haller M. Coronary artery disease in youth: present markers, future hope? J Pediatr. 2010;157(4):523-524.

Singhal A, Cole TJ, Fewtrell M, et al. Breast milk feeding and lipoprotein profile in adolescents born preterm: follow-up of a prospective randomized study. Lancet. 2004;363:1571-1578.

Wald DS, Bestwick JP, Wald NJ. Child-parent screening for familial hypercholesterolaemia: screening strategy based on a meta-analysis. BMJ. 2007;335:599-603.

Wiegman A, Hutten BA, de Groot E, et al. Efficacy and safety of statin therapy in children with familial hypercholesterolemia. JAMA. 2004;292:331-337.

80.4 Lipidoses (Lysosomal Storage Disorders)

The lysosomal lipid storage diseases are diverse disorders each due to an inherited deficiency of a lysosomal hydrolase leading to the intralysosomal accumulation of the enzyme’s particular substrate (Tables 80-16 and 80-17). With the exception of Wolman disease and cholesterol ester storage disease, the lipid substrates share a common structure that includes a ceramide backbone (2-N-acylsphingosine) from which the various sphingolipids are derived by substitution of hexoses, phosphorylcholine, or one or more sialic acid residues on the terminal hydroxyl group of the ceramide molecule. The pathway of sphingolipid metabolism in nervous tissue (Fig. 80-15) and in visceral organs (Fig. 80-16) is known; each catabolic step, with the exception of the catabolism of lactosylceramide, has a genetically determined metabolic defect and a resultant disease. Because sphingolipids are essential components of all cell membranes, the inability to degrade these substances and their subsequent accumulation results in the physiologic and morphologic alterations and characteristic clinical manifestations of the lipid storage disorders (see Table 80-16). Progressive lysosomal accumulation of glycosphingolipids in the central nervous system leads to neurodegeneration, whereas storage in visceral cells can lead to organomegaly, skeletal abnormalities, pulmonary infiltration, and other manifestations. The storage of a substrate in a specific tissue is dependent on its normal distribution in the body.

Table 80-17 SYMPTOMS ENCOUNTERED IN PATIENTS WITH LYSOSOMAL STORAGE DISORDERS

System Manifestations
Neurologic Hypotonia
Floppy-infant syndrome
Trismus
Strabismus
Opisthotonus
Spasticity
Seizures
Peripheral neuropathy
Developmental delay
Irritability
Extrapyramidal movement disorder
Hydrocephalus
Respiratory Congenital lobar emphysema
Impaired cough
Recurrent respiratory infections
Hoarseness
Endocrine Osteopenia
Metabolic bone disease
Secondary hyperparathyroidism
Congenital adrenal hyperplasia
Cardiovascular Cardiomegaly
Congenital heart failure
Arrhythmias
Wolff-Parkinson-White syndrome
Cardiomyopathy
Dysmorphology  
Head and neck Microcephaly
Enlarged nuchal translucency
Microstomia
Micrognathia/microretrognathia
Long philtrums
Limbs Bilateral broad thumbs and toes
Bilateral club feet
Eversed lips
Flattened nasal bridge
Short nasal columella
Oral Macroglossia
  Molar hypoplasia
  Hypertrophic gums
  Absent nasal septum
  Bilateral epicanthal inferior orbital creases
  Palpebral edema
  Hypertelorism
Facial Coarse facies
  Low-set ears
Gastrointestinal Hepatosplenomegaly
  Neonatal cholestasis
Bones and joints Lytic bone lesions
  Joint contractures
  Dysostosis multiplex
  Hyperphosphatasemia
  Vertebral breaking
  Broadening of tubular bones
  Punctuate epiphysis
  Craniosynostosis
  Painful joint swelling
Skin Congenital ichthyosis
  Collodion infant
  Hypopigmentation
  Telangiectasias
  Extended Mongolian spots
Ocular Corneal clouding
  Megalocornea
  Glaucoma
  Cherry-red spots
  Fundi hypopigmentation
  Bilateral cataracts
Hematologic Anemia
  Thrombocytopenia
Hydrops fetalis NIHF
  Congenital ascites
Recurrent fetal losses  

From Staretz-Chacham O, Lang TC, LaMarca ME, et al: Lysosomal storage disorders in the newborn, Pediatrics 123:1191–1207, 2009.

Diagnostic assays for the identification of affected individuals rely on the measurement of the specific enzymatic activity in isolated leukocytes or cultured fibroblasts or lymphoblasts. An approach to differentiating these disorders is noted in Figure 80-17. For most disorders, carrier identification and prenatal diagnosis are available; a specific diagnosis is essential to permit genetic counseling. The characterization of the genes that encode the specific enzymes required for sphingolipid metabolism permit the development of therapeutic options, such as recombinant enzyme replacement therapy, as well as the potential of cell or gene therapy. Identification of specific disease-causing mutations improves diagnosis, prenatal detection, and carrier identification. For several disorders (Gaucher, Fabry, and Niemann-Pick disease), it has been possible to make genotype-phenotype correlations that predict disease severity and allow more precise genetic counseling. Inheritance is autosomal recessive except for X-linked Fabry disease.

image

Figure 80-17 Algorithm of the clinical evaluation recommended for an infant with a suspected lysosomal storage disease. GAGs, glycosaminoglycans; NIHF, nonimmune hydrops fetalis.

(From Staretz-Chacham O, Lang TC, LaMarca ME, et al: Lysosomal storage disorders in the newborn, Pediatrics 123:1191–1207, 2009.)

GM1 Gangliosidosis

GM1 gangliosidosis most frequently presents in early infancy, but has been described in patients with a juvenile and onset subtypes. Inherited as an autosomal recessive trait, each subtype results from a different gene mutation that leads to the deficient activity of β-galactosidase, a lysosomal enzyme encoded by a gene on chromosome 3 (3p21.33). Although the disorder is characterized by the pathologic accumulation of GM1 gangliosides in the lysosomes of both neural and visceral cells, GM1 ganglioside accumulation is most marked in the brain. In addition, keratan sulfate, a mucopolysaccharide, accumulates in liver and is excreted in the urine of patients with GM1 gangliosidosis. The β-galactosidase gene has been isolated and sequenced; mutations causing the disease subtypes have been identified.

The clinical manifestations of the infantile form of GM1 gangliosidosis may be evident in the newborn as hepatosplenomegaly, edema, and skin eruptions (angiokeratoma). It most frequently presents in the first 6 mo of life with developmental delay followed by progressive psychomotor retardation and the onset of tonic-clonic seizures. A typical facies is characterized by low-set ears, frontal bossing, a depressed nasal bridge, and an abnormally long philtrum. Up to 50% of patients have a macular cherry red spot. Hepatosplenomegaly and skeletal abnormalities similar to those of the mucopolysaccharidoses, including anterior beaking of the vertebrae, enlargement of the sella turcica, and thickening of the calvarium, are present. By the end of the first year of life, most patients are blind and deaf, with severe neurologic impairment characterized by decerebrate rigidity. Death usually occurs by 3-4 yr of age. The juvenile-onset form of GM1 gangliosidosis is clinically distinct, with a variable age at onset. Affected patients present primarily with neurologic symptoms including ataxia, dysarthria, mental retardation, and spasticity. Deterioration is slow; patients may survive through the 4th decade of life. These patients lack the visceral involvement, facial abnormalities, and skeletal features seen in type 1 disease. Adult-onset patients have been described who present with gait and speech abnormalities, dystonia and mild skeletal abnormalities. There is no specific treatment for either form of GM1 gangliosidosis.

The diagnosis of GM1 gangliosidosis should be suspected in infants with typical clinical features and is confirmed by the demonstration of the deficiency of β-galactosidase activity in peripheral leukocytes. Other disorders that share some of the features of the GM1 gangliosidoses include Hurler disease (mucopolysaccharidosis type I), I-cell disease, and Niemann-Pick disease (NPD) type A, which can each be distinguished by the demonstration of their specific enzymatic deficiencies. Carriers of the disorder are detected by the measurement of the enzymatic activity in peripheral leukocytes or by identifying the specific gene mutations; prenatal diagnosis is accomplished by determination of the enzymatic activity in cultured amniocytes or chorionic villi. Currently only supportive therapy is available for patients with GM1 gangliosidosis.

The GM2 Gangliosidoses

The GM2 gangliosidoses include Tay-Sachs disease and Sandhoff disease; each results from the deficiency of β-hexosaminidase activity and the lysosomal accumulation of GM2 gangliosides, particularly in the central nervous system. Both disorders have been classified into infantile-, juvenile-, and adult-onset forms based on the age at onset and clinical features. β-Hexosaminidase occurs as 2 isozymes: β-hexosaminidase A, which is composed of 1 α and 1 β subunit, and β-hexosaminidase B, which has 2 β subunits. β-Hexosaminidase A deficiency results from mutations in the α subunit and causes Tay-Sachs disease, whereas mutations in the β-subunit gene result in the deficiency of both β-hexosaminidases A and B and cause Sandhoff disease. Both are autosomal recessive traits, with Tay-Sachs disease having a predilection for the Ashkenazi Jewish population, where the carrier frequency is about 1/25.

More than 50 mutations have been identified; most are associated with the infantile forms of disease. Three mutations account for >98% of mutant alleles among Ashkenazi Jewish carriers of Tay-Sachs disease, including one allele associated with the adult-onset form. Mutations that cause the subacute or chronic forms result in enzyme proteins with residual enzymatic activities, the levels of which correlate with the severity of the disease.

Patients with the infantile form of Tay-Sachs disease have clinical manifestations in infancy including loss of motor skills, increased startle reaction, and macular pallor and retinal cherry red spots (see Table 80-16). Affected infants usually develop normally until 4-5 mo of age when decreased eye contact and an exaggerated startle response to noise (hyperacusis) are noted. Macrocephaly, not associated with hydrocephalus, may develop. In the 2nd yr of life, seizures develop which may be refractory to anticonvulsant therapy. Neurodegeneration is relentless, with death occurring by the age of 4 or 5 yr. The juvenile and later-onset forms initially present with ataxia and dysarthria and may not be associated with a macular cherry red spot.

The clinical manifestations of Sandhoff disease are similar to those for Tay-Sachs disease. Infants with Sandhoff disease have hepatosplenomegaly, cardiac involvement, and mild bony abnormalities. The juvenile form of this disorder presents as ataxia, dysarthria, and mental deterioration, but without visceral enlargement or a macular cherry red spot. There is no treatment available for Tay-Sachs disease or Sandhoff disease, although experimental approaches are being evaluated.

The diagnosis of infantile Tay-Sachs disease and Sandhoff disease is usually suspected in an infant with neurologic features and a cherry red spot. Definitive diagnosis is made by determination of β-hexosaminidase A and B activities in peripheral leukocytes. The two disorders are distinguished by the enzymatic assay, because in Tay-Sachs disease only the β-hexosaminidase A isozyme is deficient, whereas in Sandhoff disease both the β-hexosaminidase A and B isozymes are deficient. Future at-risk pregnancies for both disorders can be prenatally diagnosed by determining the enzyme levels in fetal cells obtained by amniocentesis or chorionic villus sampling. Identification of carriers in families is also possible by β-hexosaminidases A and B determination. Indeed, for Tay-Sachs disease, carrier screening of all couples in which at least one member is of Ashkenazi Jewish descent is recommended before the initiation of pregnancy to identify couples at risk. These studies can be conducted by the determination of the level of β-hexosaminidase A activity in peripheral leukocytes or plasma. Molecular studies to identify the exact molecular defect in enzymatically identified carriers should also be performed to permit more specific identification of carriers in the family and to allow prenatal diagnosis in at-risk couples by both enzymatic and genotype determinations. The incidence of Tay-Sachs disease has been markedly reduced since the introduction of carrier screening programs in the Ashkenazi Jewish population. Newborn screening may be possible by measuring specific glycosphingolipid markers, or the relevant enzymatic activities in dried blood spots.

Gaucher Disease

This disease is a multisystemic lipidosis characterized by hematologic abnormalities, organomegaly, and skeletal involvement, the latter usually manifesting as bone pain and pathologic fractures (see Table 80-16). It is the most common lysosomal storage disease and the most prevalent genetic defect among Ashkenazi Jews. There are 3 clinical subtypes delineated by the absence or presence and progression of neurologic manifestations: type 1 or the adult, non-neuronopathic form; type 2, the infantile or acute neuronopathic form; and type 3, the juvenile or subacute neuronopathic form. All are autosomal recessive traits. Type 1, which accounts for 99% of cases, has a striking predilection for Ashkenazi Jews, with an incidence of about 1/1,000 and a carrier frequency of about 1/18.

Gaucher disease results from the deficient activity of the lysosomal hydrolase, acid β-glucosidase, which is encoded by a gene located on chromosome 1q21-q31. The enzymatic defect results in the accumulation of undegraded glycolipid substrates, particularly glucosylceramide, in cells of the reticuloendothelial system. This progressive deposition results in infiltration of the bone marrow, progressive hepatosplenomegaly, and skeletal complications. Four mutations—N370S, L444P, 84insG, and IVS2—account for about 95% of mutant alleles among Ashkenazi Jewish patients, permitting screening for this disorder in this population. Genotype-phenotype correlations have been noted, providing the molecular basis for the clinical heterogeneity seen in Gaucher disease type 1. Patients who are homozygous for the N370S mutation tend to have later onset, with a more indolent course than patients with one copy of N370S and another common allele.

Clinical manifestations of type 1 Gaucher disease have a variable age at onset, from early childhood to late adulthood, with most symptomatic patients presenting by adolescence. At presentation, patients may have bruising from thrombocytopenia, chronic fatigue secondary to anemia, hepatomegaly with or without elevated liver function test results, splenomegaly, and bone pain. Occasional patients have pulmonary involvement at the time of presentation. Patients presenting in the first decade frequently are not Jewish and have growth retardation and a more malignant course. Other patients may be discovered fortuitously during evaluation for other conditions or as part of routine examinations; these patients may have a milder or even a benign course. In symptomatic patients, splenomegaly is progressive and can become massive. Most patients develop radiologic evidence of skeletal involvement, including an Erlenmeyer flask deformity of the distal femur. Clinically apparent bony involvement, which occurs in most patients, can present as bone pain, a pseudo-osteomyelitis pattern or pathologic fractures. Lytic lesions can develop in the long bones, including the femur, ribs, and pelvis; osteosclerosis may be evident at an early age. Bone crises with severe pain and swelling can occur. Bleeding secondary to thrombocytopenia may manifest as epistaxis or bruising and is frequently overlooked until other symptoms become apparent. With the exception of the severely growth-retarded child, who may experience developmental delay secondary to the effects of chronic disease, development and intelligence are normal.

The pathologic hallmark of Gaucher disease is the Gaucher cell in the reticuloendothelial system, particularly in the bone marrow (Fig. 80-18). These cells, which are 20-100 µm in diameter, have a characteristic wrinkled paper appearance resulting from the presence of intracytoplasmic substrate inclusions. The cytoplasm of the Gaucher cell reacts strongly positive with the periodic acid–Schiff stain. The presence of this cell in bone marrow and tissue specimens is highly suggestive of Gaucher disease, although it also may be found in patients with granulocytic leukemia and myeloma.

Gaucher disease type 2 is much less common and does not have an ethnic predilection. It is characterized by a rapid neurodegenerative course with extensive visceral involvement and death within the first years of life. It presents in infancy with increased tone, strabismus, and organomegaly. Failure to thrive and stridor caused by laryngospasm are typical. After a several-year period of psychomotor regression, death occurs secondary to respiratory compromise. Gaucher disease type 3 presents as clinical manifestations that are intermediate to those seen in types 1 and 2, with presentation in childhood and death by age 10-15 yr. It has a predilection for the Swedish Norrbottnian population, among which the incidence is about 1/50,000. Neurologic involvement is present. Type 3 disease is further classified as types 3a and 3b based on the extent of neurologic involvement and whether there is progressive myotonia and dementia (type 3a) or isolated supranuclear gaze palsy (type 3b).

Gaucher disease should be considered in the differential diagnosis of patients with unexplained organomegaly, who bruise easily, have bone pain, or have a combination of these conditions. Bone marrow examination usually reveals the presence of Gaucher cells. All suspected diagnoses should be confirmed by determination of the acid β-glucosidase activity in isolated leukocytes or cultured fibroblasts. In Ashkenazi Jewish individuals the identification of carriers can be achieved best by molecular testing for the common mutations. Testing should be offered to all family members, keeping in mind that heterogeneity, even among members of the same kindred, can be so great that nonsymptomatic affected individuals may be diagnosed. Prenatal diagnosis is available by determination of enzyme activity and/or the specific family mutations in chorionic villi or cultured amniotic fluid cells.

Treatment of patients with Gaucher disease type 1 includes enzyme replacement therapy, with recombinant acid β-glucosidase (imiglucerase). Most extraskeletal symptoms (organomegaly, hematologic indices) are reversed by enzyme (60 IU/kg) administered by intravenous infusion every other week. Monthly maintenance enzyme replacement improves bone structure, decreases bone pain, and induces compensatory growth in affected children. A small number of patients have undergone bone marrow transplantation, which is curative but results in significant morbidity and mortality from the procedure, making the selection of appropriate candidates limited. Although enzyme replacement does not alter the neurologic progression of patients with Gaucher disease types 2 and 3, it has been used in selected patients as a palliative measure, particularly in type 3 patients with severe visceral involvement. Alternative treatments, including the use of agents designed to decrease the synthesis of glucosylceramide by chemical inhibition of glucosylceramide synthase, are available for patients who cannot be treated by enzyme replacement.

Neimann-Pick Disease (NPD)

The original description of NPD was what is now known as type A NPD, a fatal disorder of infancy characterized by failure to thrive, hepatosplenomegaly, and a rapidly progressive neurodegenerative course that leads to death by 2-3 yr of age. Type B disease is a non-neuronopathic form observed in children and adults. Type C disease is a neuronopathic form that results from defective cholesterol transport. All subtypes are inherited as autosomal recessive traits and display variable clinical features (see Table 80-16).

NPD types A and B result from the deficient activity of acid sphingomyelinase, a lysosomal enzyme encoded by a gene on chromosome 11 (11p15.1-p15.4). The enzymatic defect results in the pathologic accumulation of sphingomyelin, a ceramide phospholipid, and other lipids in the monocyte-macrophage system the primary pathologic site. The progressive deposition of sphingomyelin in the central nervous system results in the neurodegenerative course seen in type A, and in non-neural tissue in the systemic disease manifestations of type B, including progressive lung disease in some patients. A variety of mutations in the acid sphingomyelinase gene that cause types A and B NPD have been identified.

The clinical manifestations and course of type A NPD is uniform and is characterized by a normal appearance at birth. Hepatosplenomegaly, moderate lymphadenopathy, and psychomotor retardation are evident by 6 mo of age, followed by neurodevelopmental regression and death by 3 yr. With advancing age, the loss of motor function and the deterioration of intellectual capabilities are progressively debilitating; and in later stages, spasticity and rigidity are evident. Affected infants lose contact with their environment. In contrast to the stereotyped type A phenotype, the clinical presentation and course of patients with type B disease are more variable. Most are diagnosed in infancy or childhood when enlargement of the liver or spleen, or both, is detected during a routine physical examination. At diagnosis, type B NPD patients usually have evidence of mild pulmonary involvement, usually detected as a diffuse reticular or finely nodular infiltration on the chest radiograph. Pulmonary symptoms usually present in adults. In most patients, hepatosplenomegaly is particularly prominent in childhood, but with increasing linear growth, the abdominal protuberance decreases and becomes less conspicuous. In mildly affected patients, the splenomegaly may not be noted until adulthood, and there may be minimal disease manifestations.

In some type B patients, decreased pulmonary diffusion caused by alveolar infiltration becomes evident in late childhood or early adulthood and progresses with age. Severely affected individuals may experience significant pulmonary compromise by 15-20 yr of age. Such patients have low PO2 values and dyspnea on exertion. Life-threatening bronchopneumonias may occur, and cor pulmonale has been described. Severely affected patients may have liver involvement leading to life-threatening cirrhosis, portal hypertension, and ascites. Clinically significant pancytopenia due to secondary hypersplenism may require partial or complete splenectomy; this should be avoided if possible because splenectomy frequently causes progression of pulmonary disease, which can be life-threatening. In general, type B patients do not have neurologic involvement and have a normal IQ. Some patients with type B disease have cherry red maculae or haloes and subtle neurologic symptoms (peripheral neuropathy).

Type C NPD patients often present with prolonged neonatal jaundice, appear normal for 1-2 yr, and then experience a slowly progressive and variable neurodegenerative course. Their hepatosplenomegaly is less severe than that of patients with types A or B NPD, and they may survive into adulthood. The underlying biochemical defect in type C patients is an abnormality in cholesterol transport, leading to the accumulation of sphingomyelin and cholesterol in their lysosomes and a secondary partial reduction in acid sphingomyelinase activity (Chapter 80.3).

In type B NPD patients, splenomegaly is usually the first manifestation detected. The splenic enlargement is noted in early childhood; in very mild disease, the enlargement may be subtle and detection may be delayed until adolescence or adulthood. The presence of the characteristic NPD cells in bone marrow aspirates supports the diagnosis of type B NPD. Patients with type C NPD, however, also have extensive infiltration of NPD cells in the bone marrow and, thus, all suspected cases should be evaluated enzymatically to confirm the clinical diagnosis by measuring the acid sphingomyelinase activity level in peripheral leukocytes, cultured fibroblasts, or lymphoblasts, or a combination of these cells. Patients with types A and B NPD have markedly decreased levels (1-10%), whereas patients with type C NPD have normal or somewhat decreased acid sphingomyelinase activities. The enzymatic identification of NPD carriers is problematic. In families in which the specific molecular lesion has been identified, however, family members can be accurately tested for heterozygote status by DNA analysis. Prenatal diagnosis of types A and B NPD can be made reliably by the measurement of acid sphingomyelinase activity in cultured amniocytes or chorionic villi; molecular analysis of fetal cells can provide the specific diagnosis or serve as a confirmatory test. The clinical diagnosis of type C NPD can be supported by the demonstration of filipin stain positivity in cultured fibroblasts and/or by identifying a specific mutation in the NPC gene.

Currently there is no specific treatment for NPD. Orthotopic liver transplantation in an infant with type A disease and amniotic cell transplantation in several type B NPD patients have been attempted with little or no success. Bone marrow transplantation in a small number of type B NPD patients has been shown to be successful in reducing the spleen and liver volumes, the sphingomyelin content of the liver, the number of Niemann-Pick cells in the marrow, and radiologically detected infiltration of the lungs. In one patient, liver biopsies taken up to 33 mo post transplantation showed only a moderate reduction in stored sphingomyelin. To date, lung transplantation has not been performed in any severely compromised patient with type B disease, although two patients who underwent whole lung lavages with variable results have been reported. A phase I trial of enzyme replacement therapy for type B NPD has been completed and further clinical studies to evaluate effectiveness of this approach are planned. Clinical trials of miglustat (Acetelion, Basel, Switzerland) have been performed and the drug has been approved in Europe for the treatment of type C disease. Treatment of type A disease by bone marrow transplantation has not been successful presumably due to the severe neurologic involvement.

Fabry Disease

This condition is an X-linked inborn error of glycosphingolipid metabolism characterized by angiokeratomas (telangiectatic skin lesions), hypohidrosis, corneal and lenticular opacities, acroparesthesias, and vascular disease of the kidney, heart, and/or brain (see Table 80-16). The classic phenotype is due to the deficient activity of the enzyme α-galactosidase A and has an estimated prevalence of approximately 1/50,000 males. Later-onset affected males with residual α-galactosidase A activity may present with cardiac and/or renal disease including hypertrophic cardiomyopathy and renal failure and is more prevalent than the classic phenotype. Heterozygous females for the classic phenotype can be asymptomatic or as severely affected as the males, the variability due to random X-inactivation. The disease results from mutations in the α-galactosidase A gene located on the long arm of the X chromosome (Xq22). The enzymatic defect leads to the systemic accumulation of neutral glycosphingolipids, primarily globotriaosylceramide, particularly in the plasma and lysosomes of vascular endothelial and smooth muscle cells. The progressive vascular glycosphingolipid deposition in classically affected males results in ischemia and infarction, leading to the major disease manifestations. The cDNA and genomic sequences encoding α-galactosidase A have identified more than 500 different mutations in the α-galactosidase A gene that are responsible for this lysosomal storage disease, including amino acid substitutions, gene rearrangements, and mRNA splicing defects.

Affected males with the classic phenotype have the skin lesions, acroparesthesias, hypohidrosis, and ocular changes, whereas males with the later onset phenotypes lack these findings and present with cardiac and/or renal disease in adulthood. The classic angiokeratomas usually occur in childhood and may lead to early diagnosis (Fig. 80-19). They increase in size and number with age and range from barely visible to several mm in diameter. The lesions are punctate, dark red to blue-black, and flat or slightly raised. They do not blanch with pressure, and the larger ones may show slight hyperkeratosis. Characteristically, the lesions are most dense between the umbilicus and knees, in the “bathing trunk area,” but may occur anywhere, including the oral mucosa. The hips, thighs, buttocks, umbilicus, lower abdomen, scrotum, and glans penis are common sites, and there is a tendency toward symmetry. Variants without skin lesions have been described. Sweating is usually decreased or absent. Corneal opacities and characteristic lenticular lesions, observed under slit-lamp examination, are present in affected males as well as in about 90% of heterozygotes. Conjunctival and retinal vascular tortuosity is common and results from the systemic vascular involvement.

Pain is the most debilitating symptom in childhood and adolescence. Fabry crises, lasting from minutes to several days, consist of agonizing, burning pain in the hands, feet, and proximal extremities and are usually associated with exercise, fatigue, fever, or a combination of these factors. These painful acroparesthesias usually become less frequent in the 3rd and 4th decades of life, although in some men, they may become more frequent and severe. Attacks of abdominal or flank pain may simulate appendicitis or renal colic.

The major morbid symptoms result from the progressive involvement of the vascular system. Early in the course of the disease, casts, red cells, and lipid inclusions with characteristic birefringent “Maltese crosses” appear in the urinary sediment. Proteinuria, isosthenuria, and gradual deterioration of renal function and development of azotemia occur in the 2nd through 4th decades. Cardiovascular findings may include hypertension, left ventricular hypertrophy, anginal chest pain, myocardial ischemia or infarction, and heart failure. Mitral insufficiency is the most common valvular lesion. Abnormal electrocardiographic and echocardiographic findings are common. Cerebrovascular manifestations result from multifocal small vessel involvement. Other features may include chronic bronchitis and dyspnea, lymphedema of the legs without hypoproteinemia, episodic diarrhea, osteoporosis, retarded growth, and delayed puberty. Death most often results from uremia or vascular disease of the heart or brain. Before hemodialysis or renal transplantation, the mean age at death for affected men was 40 yr. Patients with the later onset phenotype with residual α-galactosidase A activity have cardiac and/or renal disease. The cardiac manifestations include hypertrophy of the left ventricular wall and interventricular septum, and electrocardiographic abnormalities consistent with cardiomyopathy. Others have had hypertrophic cardiomyopathy or myocardial infarction, or both.

The diagnosis in classically affected males is most readily made from the history of painful acroparesthesias, hypohidrosis, the presence of characteristic skin lesions, and the observation of the characteristic corneal opacities and lenticular lesions. The disorder is often misdiagnosed as rheumatic fever, erythromelalgia, or neurosis. The skin lesions must be differentiated from the benign angiokeratomas of the scrotum (Fordyce disease) or from angiokeratoma circumscriptum. Angiokeratomas identical to those of Fabry disease have been reported in fucosidosis, aspartylglycosaminuria, late-onset GM1 gangliosidosis, galactosialidosis, α-N-acetylgalactosaminidase deficiency, and sialidosis. Later onset patients have been identified among patients on hemodialysis and among patients with hypertrophic cardiomyopathy or who have suffered cryptogenic strokes. Later-onset patients lack the early classic manifestations such as the angiokeratomas, acroparesthesias, hypohidrosis, and corneal opacities. The diagnosis of classic and later-onset patients is confirmed biochemically by the demonstration of markedly decreased α-galactosidase A activity in plasma, isolated leukocytes, or cultured fibroblasts or lymphoblasts.

Heterozygous females may have corneal opacities, isolated skin lesions, and intermediate activities of α-galactosidase A in plasma or cells. Rare female heterozygotes may have manifestations as severe as those in affected males. Asymptomatic at-risk females in families affected by Fabry disease, however, should be optimally diagnosed by the direct analysis of their family’s specific mutation. Prenatal detection of affected males can be accomplished by the demonstration of deficient α-galactosidase A activity or the family’s specific gene mutation in chorionic villi obtained in the 1st trimester or in cultured amniocytes obtained by amniocentesis in the 2nd trimester of pregnancy. Fabry disease can be detected by newborn screening and pilot studies have been conducted in Italy and Taiwan.

Treatment for Fabry disease may include the use of phenytoin and/or carbamazepine to decrease the frequency and severity of the chronic acroparesthesias and the periodic crises of excruciating pain. Renal transplantation and long-term hemodialysis are lifesaving procedures for patients with renal failure.

Recombinant α-galactosidase (Fabrazyme, Genzyme Corporation, Cambridge, Mass; Replagal, Shire, UK) is a safe and effective enzyme replacement therapy of choice for Fabry disease at a dose of 1 mg/kg every other week. It has been shown to clear microvascular endothelial deposits of globotriaosylceramide from the kidneys, heart, and skin in patients with Fabry disease with stabilization of renal disease, regression of hypertrophic cardiomyopathy, reduction of pain, and improvement in quality of life.

Fucosidosis

This is a rare autosomal recessive disorder caused by the deficient activity of α-fucosidase and the accumulation of fucose-containing glycosphingolipids, glycoproteins, and oligosaccharides in the lysosomes of the liver, brain, and other organs (see Table 80-16). The α-fucosidase gene is on chromosome 1 (1p24), and specific mutations are known. Although the disorder is panethnic, most affected patients are from Italy and the USA. There is wide variability in the clinical phenotype, with the most severely affected patients presenting in the first year of life with developmental delay and somatic features similar to those of the mucopolysaccharidoses. These features include frontal bossing, hepatosplenomegaly, coarse facial features, and macroglossia. The central nervous system storage results in a relentless neurodegenerative course, with death in childhood. Patients with milder disease have angiokeratomas and longer survival. No specific therapy exists for the disorder, which can be diagnosed by the demonstration of deficient α-fucosidase activity in peripheral leukocytes or cultured fibroblasts. Carrier identification studies and prenatal diagnosis are possible by determination of the enzymatic activity or the specific family mutations.

Schindler Disease

This is an autosomal recessive neurodegenerative disorder that results from the deficient activity of α-N-acetylgalactosaminidase and the accumulation of sialylated and asialoglycopeptides and oligosaccharides (see Table 80-16). The gene for the enzyme is located on chromosome 22 (22q11). The disease is clinically heterogeneous, and two major phenotypes have been identified. Type I disease is an infantile-onset neuroaxonal dystrophy. Affected infants have normal development for the 1st 9-15 mo of life followed by a rapid neurodegenerative course that results in severe psychomotor retardation, cortical blindness, and frequent myoclonic seizures. Type II disease is characterized by a variable age at onset, mild retardation, and angiokeratomas. There is no specific therapy for either form of the disorder. The diagnosis is by demonstration of the enzymatic deficiency in leukocytes or cultured skin fibroblasts or specific gene mutations.

Metachromatic Leukodystrophy (MLD)

This is an autosomal recessive white matter disease caused by a deficiency of arylsulfatase A (ASA), which is required for the hydrolysis of sulfated glycosphingolipids. Another form of MLD is caused by a deficiency of a sphingolipid activator protein (SAP1), which is required for the formation of the substrate-enzyme complex. The deficiency of this enzymatic activity results in the white matter storage of sulfated glycosphingolipids, which leads to demyelination and a neurodegenerative course. The ASA gene is on chromosome 22 (22q13.31qter); specific mutations are known to fall into two groups that correlate with disease severity.

The clinical manifestations of the late infantile form of MLD, which is most common, usually presents between 12 and 18 mo of age as irritability, inability to walk, and hyperextension of the knee, causing genu recurvatum. The clinical progression of the disease relates to the pathological involvement of both central and peripheral nervous system, giving a mixture of upper and lower motor neuron and cognitive and psychiatric signs. Deep tendon reflexes are diminished or absent. Gradual muscle wasting, weakness, and hypotonia become evident and lead to a debilitated state. As the disease progresses, nystagmus, myoclonic seizures, optic atrophy, and quadriparesis appear, with death in the 1st decade of life (see Table 80-16). The juvenile form of the disorder has a more indolent course with onset that may occur as late as 20 yr of age. This form of the disease presents with gait disturbances, mental deterioration, urinary incontinence, and emotional difficulties. The adult form, which presents after the 2nd decade, is similar to the juvenile form in its clinical manifestations, although emotional difficulties and psychosis are more prominent features. Dementia, seizures, diminished reflexes, and optic atrophy also occur in both the juvenile and adult forms. The pathologic hallmark of MLD is the deposition of metachromatic bodies, which stain strongly positive with periodic acid–Schiff and Alcian blue, in the white matter of the brain. Neuronal inclusions may be seen in the midbrain, pons, medulla, retina, and spinal cord; demyelination occurs in the peripheral nervous system. Bone marrow transplantation has resulted in normal enzymatic levels in peripheral blood, but no clear evidence for clinical efficacy in terms of the neurologic course; supportive care remains the primary intervention.

The diagnosis of MLD should be suspected in patients with the clinical features of leukodystrophy. Decreased nerve conduction velocities, increased cerebrospinal fluid protein, metachromatic deposits in sampled segments of sural nerve, and metachromatic granules in urinary sediment are all suggestive of MLD. Confirmation of the diagnosis is based on the demonstration of the reduced activity of ASA in leukocytes or cultured skin fibroblasts. Sphingolipid activator protein deficiency is diagnosed by measuring the concentration of SAP1 in cultured fibroblasts using a specific antibody to the protein. Carrier detection and prenatal diagnosis is available for all forms of the disorder.

Krabbe Disease

This condition, also called globoid cell leukodystrophy, is an autosomal recessive fatal disorder of infancy. It results from the deficiency of the enzymatic activity of galactocerebrosidase (GALC) and the white matter accumulation of galactosylceramide, which is normally found almost exclusively in the myelin sheath. Both peripheral and central myelin are affected, resulting in spasticity and cognitive impairment coupled with deceptively normal or even absent deep tendon reflexes. The galactocerebrosidase gene is on chromosome 14 (14q31), and specific disease-causing mutations are known. The infantile form of Krabbe disease is rapidly progressive and patients present in early infancy with irritability, seizures, and hypertonia (see Table 80-16). Optic atrophy is evident in the 1st yr of life, and mental development is severely impaired. As the disease progresses, optic atrophy and severe developmental delay become apparent; affected children exhibit opisthotonos and die before 3 yr of age. A 2nd, late infantile form of Krabbe disease also exists and patients present after the age of 2 yr. Affected individuals have a disease course similar to that of the early infantile form.

The diagnosis of Krabbe disease relies on the demonstration of the specific enzymatic deficiency in white blood cells or cultured skin fibroblasts. Causative gene mutations have been identified. Carrier identification and prenatal diagnosis are available. The development of methods to measure GALC activity on dried blood spots has led to the inclusion of Krabbe disease in the newborn screening programs of some states. Treatment of infants with Krabbe disease with umbilical cord blood cell transplantation has been reported in prenatally identified asymptomatic newborns and symptomatic infants. The long term outcome of umbilical cord blood cell transplantation is being evaluated; transplanted infants develop neurologic manifestations at a slower rate but succumb to a neurologic demise.

Farber Disease

This is a rare autosomal recessive disorder that results from the deficiency of the lysosomal enzyme acid ceramidase and the accumulation of ceramide in various tissues, especially the joints. Symptoms can begin as early as the 1st year of life with painful joint swelling and nodule formation (Fig. 80-20), which is sometimes diagnosed as rheumatoid arthritis. As the disease progresses, nodule or granulomatous formation on the vocal cords can lead to hoarseness and breathing difficulties; failure to thrive is common. In some patients, moderate central nervous system dysfunction is present (see Table 80-16). Patients may die of recurrent pneumonias in their teens; there is currently no specific therapy. The diagnosis of this disorder should be suspected in patients who have nodule formation over the joints but no other findings of rheumatoid arthritis. In such patients, ceramidase activity should be determined in cultured skin fibroblasts or peripheral leukocytes. Various disease causing mutations have been identified in the acid ceramidase gene. Carrier detection and prenatal diagnosis are available.

Wolman Disease and Cholesterol Ester Storage Disease (CESD)

These are autosomal recessive lysosomal storage diseases that result from the deficiency of acid lipase and the accumulation of cholesterol esters and triglycerides in histiocytic foam cells of most visceral organs. The gene for lysosomal acid lipase is on chromosome 10 (10q24-q25). Wolman disease is the more severe clinical phenotype and is a fatal disorder of infancy. Clinical features become apparent in the 1st wk of life and include failure to thrive, relentless vomiting, abdominal distention, steatorrhea, and hepatosplenomegaly (see Table 80-16). There usually is hyperlipidemia. Hepatic dysfunction and fibrosis may occur. Calcification of the adrenal glands is pathognomonic for the disorder. Death usually occurs within 6 mo.

Cholesterol ester storage disease is a less severe disorder that may not be diagnosed until adulthood. Hepatomegaly can be the only detectable abnormality, but affected individuals are at significant risk for premature atherosclerosis. Adrenal calcification is not a feature.

Diagnosis and carrier identification are based on measuring acid lipase activity in peripheral leukocytes or cultured skin fibroblasts. Disease causing mutations have been identified in the acid ceramide gene. Prenatal diagnosis depends on measuring decreased enzyme levels or identifying specific mutations in cultured chorionic villi or amniocytes. There is no specific therapy available for either disorder, although pharmacologic agents to suppress cholesterol synthesis, in combination with cholestyramine and diet modification, have been used in patients with cholesterol ester storage disease (see Chapter 80.3).

Bibliography

Andersson H, Kaplan P, Kacena K, Yee J. Eight-year clinical outcomes of long-term enzyme replacement therapy for 884 children with Gaucher disease type 1. Pediatrics. 2008;122:1182-1190.

Clark JTR. Narrative review: Fabry disease. Ann Intern Med. 2007;146:425-433.

Escolar ML, Poe MD, Provenzale JM, et al. Transplantation of umbilical-cord blood in babies with infantile Krabbe’s disease. N Engl J Med. 2005;20:2069-2080.

Grabowski GA. Phenotype, diagnosis, and treatment of Gaucher’s disease. Lancet. 2008;372:1263-1271.

Itzchaki M, Lebel E, Dweck A, et al. Orthopedic considerations in Gaucher disease since the advent of enzyme replacement therapy. Acta Orthop Scand. 2004;75:641-653.

Kaplan P, Anderson HC, Kacena KA, et al. The clinical and demographic characteristics of nonneuronpathic Gaucher disease in 887 children at diagnosis. Arch Pediatr Adolesc Med. 2006;160:603-608.

Martins AM, D’Almeida VD, Kyosen SO, et al. Guidelines to diagnosis and monitoring of Fabry disease and review of treatment experiences. J Pediatr. 2009;155:S19-S30.

McGovern MM, Wasserstein MP, Giugliani R, et al. A prospective, cross-sectional survey study of the natural history of Niemann-Pick disease type B. Pediatrics. 2008;122:e341-e349.

Mehta A, Beck M, Elliott P, et al. Enzyme replacement therapy with agalsidase alfa in patients with Fabry’s disease: an analysis of registry data. Lancet. 2009;374:1986-1996.

Meikle PJ, Ranieri E, Simonsen H, et al. Newborn screening for lysosomal storage disorders: clinical evaluation of a two-tier strategy. Pediatrics. 2004;114:909-916.

Park NJ, Morgan C, Sharma R, et al. Improving accuracy of Tay Sachs carrier screening of the non-Jewish population: analysis of 34 carriers and six late-onset patients with HEXA enzyme and DNA sequence analysis. Pediatr Res. 2010;67:217-220.

Staretz-Chachem O, Lang TC, LaMarca ME, et al. Lysosomal storage disorders in the newborn. Pediatrics. 2009;123:1191-1207.

West M, Nicholls K, Mehta A, et al. Agalsidase alfa and kidney dysfunction in Fabry disease. J Ann Soc Nephrol. 2009;20:1132-1139.

Wraith JE, Tylki-Szymanska A, Guffon N, et al. Safety and efficacy of enzyme replacement therapy with agalsidase beta: an international, open-label study in pediatric patients with Fabry disease. J Pediatr. 2008;152:563-570.

Zarate YA, Hopkin RJ. Fabry’s disease. Lancet. 2008;372:1427-1435.

80.5 Mucolipidoses

I-cell disease (mucolipidosis II [ML-II]) and pseudo-Hurler polydystrophy (mucolipidosis III [ML-III]) are rare autosomal recessive disorders that share some clinical features with Hurler syndrome (Chapter 82). These diseases result from the abnormal transport of newly synthesized lysosomal enzymes that are normally targeted to the lysosome by the presence of mannose-6-phosphate residues and recognized by specific lysosomal membrane receptors. These mannose-6-phosphate recognition markers are synthesized in a 2-step reaction that occurs in the Golgi apparatus and is mediated by 2 enzymatic activities. The enzyme that catalyzes the 1st step, the UDP-N-acetylglucosamine : lysosomal enzyme N-acetylglucosamine-1-phosphotransferase, is defective in both ML-II and ML-III, which are allelic disorders resulting from mutations in the GlcNAc-phosphotransferase alpha/beta-subunits precursor gene (GNPTAB). This enzyme deficiency results in abnormal targeting of the lysosomal enzymes that are consequently secreted into the extracellular matrix. Because the lysosomal enzymes require the acidic medium of the lysosome to function, patients with this defect accumulate a variety of different substrates due to the intracellular deficiency of all lysosomal enzymes. The diagnosis of ML-II and ML-III can be made by the determination of the serum lysosomal enzymatic activities, which are elevated, or by the demonstration of reduced enzymatic activity levels in cultured skin fibroblasts. Direct measurement of the phosphotransferase activity is possible as well. Prenatal diagnosis is available for both disorders by measurement of lysosomal enzymatic activities in amniocytes or chorionic villus cells; carrier identification studies are available for both disorders using cultured skin fibroblasts. Neonatal screening by tandem mass spectroscopy may detect I-cell disease.

I-Cell Disease

This disorder shares many of the clinical manifestations of Hurler syndrome (Chapter 82), although there is no mucopolysacchariduria and the presentation is earlier (see Table 80-16). Some patients have clinical features evident at birth, including coarse facial features, craniofacial abnormalities, restricted joint movement, and hypotonia. Nonimmune hydrops may be present in the fetus. The remainder of patients present in the first year with severe psychomotor retardation, coarse facial features, and skeletal manifestations that include kyphoscoliosis and a lumbar gibbus. Patients may also have congenital dislocation of the hips, inguinal hernias, and gingival hypertrophy. Progressive, severe psychomotor retardation leads to death in early childhood. No treatment is available.